    		                		            		                                                                                                                                          	    		   		   	  	       	            							    	    																																			    																	    	    	                             		       	                                                                                                   	        						    	    																																			    																	    	    	                             		       	                                                                                               									    	    																																			    																	    	    	                             		       	                                                                                               									    	    																																			    																	    	    	                             		       	                                                                                               	            			        	                            						    	    																																			    																	    	    	                             		       	                                                                                                                                                                                                                                       	        	                                                                                                                                                                                                                                                     <!DOCTYPE html><html><head>        	<meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1" />    <meta charset="utf-8" />        	<title>DailyMed - FLUVASTATIN- fluvastatin sodium capsule  </title>                <!--[if lt IE 9]>        <script src="//html5shim.googlecode.com/svn/trunk/html5.js"></script>    <![endif]-->    <link rel="stylesheet" type="text/css" media="screen" href="dailymed/css/skeleton.min.css" />    <link rel="stylesheet" type="text/css" media="screen" href="dailymed/css/jquery.jqzoom.min.css" />    <link rel="stylesheet" type="text/css" media="screen" href="dailymed/css/style.min.css" />    <link rel="stylesheet" type="text/css" media="screen" href="dailymed/css/header-search.min.css" />    <link rel="stylesheet" type="text/css" media="all" href="dailymed/css/responsive.min.css" />    <link rel="stylesheet" type="text/css" media="print" href="dailymed/css/print.min.css" />    <!--[if !IE]><!-->    <link rel="stylesheet" type="text/css" media="all" href="dailymed/css/responsive-tables.min.css" />    <!--<![endif]-->    <link rel="icon" href="dailymed/images/favicons/favicon.ico" type="image/x-icon" />    <link rel="shortcut icon" href="dailymed/images/favicons/favicon.ico" type="image/x-icon"/>        <link rel="apple-touch-icon" sizes="57x57" href="dailymed/images/favicons/apple-touch-icon-57x57.png">    <link rel="apple-touch-icon" sizes="114x114" href="dailymed/images/favicons/apple-touch-icon-114x114.png">    <link rel="apple-touch-icon" sizes="72x72" href="dailymed/images/favicons/apple-touch-icon-72x72.png">    <link rel="apple-touch-icon" sizes="144x144" href="dailymed/images/favicons/apple-touch-icon-144x144.png">    <link rel="apple-touch-icon" sizes="60x60" href="dailymed/images/favicons/apple-touch-icon-60x60.png">    <link rel="apple-touch-icon" sizes="120x120" href="dailymed/images/favicons/apple-touch-icon-120x120.png">    <link rel="apple-touch-icon" sizes="76x76" href="dailymed/images/favicons/apple-touch-icon-76x76.png">    <link rel="apple-touch-icon" sizes="152x152" href="dailymed/images/favicons/apple-touch-icon-152x152.png">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-196x196.png" sizes="196x196">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-160x160.png" sizes="160x160">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-96x96.png" sizes="96x96">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-16x16.png" sizes="16x16">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-32x32.png" sizes="32x32">    <meta name="msapplication-config" content="/dailymed/images/favicons/browserconfig.xml" />    <meta name="msapplication-TileColor" content="#da532c">    <meta name="msapplication-TileImage" content="/dailymed/images/favicons/mstile-144x144.png">    <meta name="description" content="" />    <meta name="keywords" content="" />     <meta name="robots" content="noimageindex, noodp, noydir" />     <meta name="viewport" id="viewport" content="width=device-width,minimum-scale=1.0,maximum-scale=10.0,initial-scale=1.0" />    <script src="/dailymed/scripts/modernizr-2.0.6.min.js"></script>        <script type="text/javascript" src="//ajax.googleapis.com/ajax/libs/jquery/1.10.2/jquery.min.js"></script>        <script type="text/javascript">        if (typeof jQuery == 'undefined')        {              document.write('\x3Cscript type="text/javascript" src="/dailymed/scripts/jquery-1.10.2.min.js">\x3C/script>');        }    </script>                	                	            	    	<script type="text/javascript">		var basepath = "/dailymed";;		var availableClasses =  new Array();;		for(var i = 0; i < availableClasses.length; i++){			availableClasses[i] = availableClasses[i].replace(/"/g, '').trim();		}		var labeltitle = "FLUVASTATIN- fluvastatin sodium capsule <br>";;		var emailLink = "";;		var emailrequest = "0";;	</script>    <script src="/dailymed/scripts/javascript-html-attribute-encoding.min.js"></script>	<script src="/dailymed/scripts/scripts.min.js"></script>        <script type='text/javascript' src="//ajax.googleapis.com/ajax/libs/jqueryui/1.11.0/jquery-ui.min.js"></script>    <script type="text/javascript">        if (typeof jQuery.ui == 'undefined')        {            document.write('\x3Cscript type="text/javascript" src="/dailymed/scripts/jquery-ui-1.10.4.custom.min.js">\x3C/script>');            document.write('\x3Clink rel="stylesheet" type="text/css" media="all" href="dailymed/css/jquery-ui-1.10.4.custom.min.css">');        }        else{            document.write('<link rel="stylesheet" href="/ajax.googleapis.com/ajax/libs/jqueryui/1.11.0/themes/smoothness/jquery-ui.min.css">');        }    </script>    <script type='text/javascript' src='/dailymed/scripts/jquery.elevateZoom-3.0.8.min.js'></script>      <script type="text/javascript" src="/dailymed/scripts/jquery.placeholder.min.js"></script>    <script src="//www.accessdata.fda.gov/spl/stylesheet/spl.js" type="text/javascript" charset="utf-8">/* */</script>    <!-- Magnific Popup core CSS file -->    <link rel="stylesheet" href="dailymed/css/magnific-popup.min.css">        <!-- Magnific Popup core JS file -->    <script src="/dailymed/scripts/jquery.magnific-popup.js"></script>        <meta name = "format-detection" content = "telephone=no"></head><body class="inner drug-info">	<div class="container_1000 bg_shadow">        <div style="width: 0; height: 0;"><a href="#" id="top-of-page"></a></div><header>	<div class="topHeader">				<ul id="skip">		<li><a href="#skip-main-content">Skip to Main Content</a></li></ul>		<nav class="topHeaderNav">        	<div class="topNIHLogo mobileview">        		<a href="http://www.nih.gov" class="top-logo" title="National Institutes of Health" target="_blank"><img src="/dailymed/images/nih-toplogo.png" alt="NIH Logo"/></a>            	<a href="/www.nlm.nih.gov" title="U.S. National Library of Medicine" target="_blank">U.S. National Library of Medicine</a></div>			<div class="container">				<div class="sixteen columns">                	<div class="topNIHLogo"><a href="http://www.nih.gov" title="National Institutes of Health" target="_blank"><img src="/dailymed/images/nih-toplogo.png" alt="NIH Logo"/></a>                    <a href="/www.nlm.nih.gov" title="U.S. National Library of Medicine" target="_blank">U.S. National Library of Medicine</a></div>					<ul>																		<li class="safety"><a title="Report Adverse Events" href="/www.accessdata.fda.gov/scripts/medwatch/" target="_blank">Report Adverse Events </a><span>|</span><a title="FDA Safety Reporting and Recalls" href="http://www.fda.gov/Safety/Recalls" target="_blank">Recalls</a></li>					</ul>				</div>			</div>		</nav>		<div class="divider"></div>	</div>	<div class="dailymedlogoprint"><img src="/dailymed/images/logo.png" alt="DailyMed" /></div>	<div class="bottomHeader">		<div class="header-image">						<div class="mobile-menu-btn closed hasjs" tabindex="0"></div><div class="mobile-menu">		<div class="mobile-menu-container">		<div class="pro-menu active">			<div class="first half">				<ul>					<li><a href="dailymed/index.cfm">Home</a></li>					<li>						News						<ul>							<li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>							<li><a href="dailymed/rss-updates.cfm">Get RSS News &amp; Updates</a></li>						</ul>					</li>					<li><a href="dailymed/about-dailymed.cfm">About Dailymed</a></li>					<li><a href="dailymed/contact-us.cfm">Contact Us</a></li>					<li>						Safety Reporting &amp; Recalls						<ul>							<li><a href="/www.accessdata.fda.gov/scripts/medwatch/">Report Adverse Events</a></li>							<li><a href="http://www.fda.gov/Safety/Recalls">FDA Saftey Recalls</a></li>						</ul>					</li>					<li>						<a href="dailymed/fda-drug-guidance.cfm">FDA Guidances &amp; Information</a>											</li>				</ul>			</div>			<div class="last half">				<ul>					<li>						NLM SPL Resources						<ul>							<li>								<a href="dailymed/spl-resources.cfm">Download Data</a>								<ul>									<li><a href="dailymed/spl-resources-all-drug-labels.cfm">- All Drug Labels</a></li>									<li><a href="dailymed/spl-resources-all-indexing-files.cfm">- All Indexing Files</a></li>									<li><a href="dailymed/spl-resources-all-mapping-files.cfm">- All Mapping Files</a></li>								</ul>							</li>							<li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>							<li><a href="dailymed/spl-resources-all-mapping-files.cfm">Articles &amp; Presentations</a></li>						</ul>					</li>					<li>						Application Development Support						<ul>							<li>								<a href="dailymed/app-support.cfm">Resources</a>								<ul>									<li><a href="dailymed/app-support-web-services.cfm">- Web Services</a></li>																		<li><a href="dailymed/app-support-mapping-files.cfm">- Mapping Files</a></li>								</ul>							</li>						</ul>					</li>					<li><a href="dailymed/help.cfm">Help</a></li>				</ul>			</div>		</div>			</div></div>			<a href="dailymed/index.cfm" class="logo" title="DailyMed">DailyMed</a>						<div class="header-search-container">				<div id="header-search">									    					    				    <form action="/dailymed/search.cfm">		<div class="searchNav">		<ul class="searchType">			<li class="all active">									<input type="radio" class="hidden" name="labeltype" id="labeltype-all" value="all" />					<label for="labeltype-all">All Drugs</label>							</li>			<li class="human">									<input type="radio" class="hidden" name="labeltype" id="labeltype-human" value="human"/>					<label for="labeltype-human">Human Drugs</label>							</li>			<li class="animal">									<input type="radio" class="hidden" name="labeltype" id="labeltype-animal" value="animal" />					<label for="labeltype-animal">Animal Drugs</label>							</li>							<li class="more-ways" id="header-search-more-ways">					<a href="#" id="more-ways-button" class="more-ways-label">More ways to search</a>					<ul id="more-ways-dropdown" class="dropdown" style="display:none;">						<li>							<a href="dailymed/advanced-search.cfm">Advanced Search</a>						</li>						<li>							<a href="dailymed/browse-drug-classes.cfm">Browse Drug Classes</a>						</li>						<li>							<a href="dailymed/archives/index.cfm">Label Archives</a>						</li>						<li>							<a class="external-link" href="http://pillbox.nlm.nih.gov" target="_blank">Tablet/Capsule ID Tool</a>						</li>					</ul>				</li>								</ul>	</div>			<div class="searchForm">					<div class="searchInput">				<input id="searchQuery" name="query" tabindex="0" type="text" placeholder="Enter drug, NDC code, drug class, or Set ID" autocorrect="off" autocapitalize="off">									<button class="search-button">  </button>							</div>								<input class="search" tabindex="0" title="Search" type="submit" value="Search">	</div></form>									</div>			</div>			<div class="mobile-search-btn" tabindex="0"></div>												<div class="header-bg">																										</div>			<div class="divider"></div>		</div>		<div class="bottomHeaderContent">									<div class="search mobile-search">				<div class="divider_10 nomargin mobileview"></div>				<div class="searchTool mobileview"></div>															<form action="/dailymed/search.cfm">		<div class="searchNav">		<ul class="searchType">			<li class="all active">									<input type="radio" class="hidden" name="labeltype" id="labeltype-all-2" value="all" />					<label for="labeltype-all-2">All Drugs</label>							</li>			<li class="human">									<input type="radio" class="hidden" name="labeltype" id="labeltype-human-2" value="human"/>					<label for="labeltype-human-2">Human Drugs</label>							</li>			<li class="animal">									<input type="radio" class="hidden"  name="labeltype" id="labeltype-animal-2" value="animal" />					<label for="labeltype-animal-2">Animal Drugs</label>							</li>								</ul>	</div>			<div class="searchForm">					<div class="searchInput">				<input id="searchToolsQuery" name="query" tabindex="0" type="text" placeholder="Enter drug, NDC code, drug class, or Set ID" autocorrect="off" autocapitalize="off">			</div>								<input class="search" tabindex="0" title="Search" type="submit" value="Search">	</div></form>								<div class="divider"></div>								<nav class="bottomHeaderNav">                <noscript>                <div class="tabletnav no-js">                    <div class="col">                        <ul>                            <li><a href="dailymed/index.cfm">Home</a></li>                            <li>News                                <ul>                                    <li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>                                    <li><a href="dailymed/rss-updates.cfm">Get RSS News & Updates</a></li>                                </ul>                            </li>                        </ul>                    </div>                                    <div class="col">                        <ul>                            <li>Search                                <ul>                                    <li><a href="dailymed/advanced-search.cfm">Advanced Search</a></li>                                    <li><a href="dailymed/browse-drug-classes.cfm">Browse Drug Classes</a></li>                                    <li><a href="dailymed/archives/index.cfm">Labels Archives</a></li>                                                                        <li><a href="http://pillbox.nlm.nih.gov">Tablet/Capsule ID Tool</a></li>                                </ul>                            </li>                        </ul>                    </div>                                    <div class="col">                        <ul>                            <li><a href="dailymed/fda-drug-guidance.cfm">FDA Guidances &amp; Information</a></li>                            <li>NLM SPL Resources                                <ul>                                    <li><a href="dailymed/spl-resources.cfm">Download Data</a>                                        <ul>                                            <li><a href="dailymed/spl-resources-all-drug-labels.cfm">All Drug Labels</a></li>                                            <li><a href="dailymed/spl-resources-all-indexing-files.cfm">All Index Files</a></li>                                            <li><a href="dailymed/spl-resources-all-mapping-files.cfm">All Mapping Files</a></li>                                        </ul>                                    </li>                                    <li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>                                    <li><a href="dailymed/spl-resources-presentations-articles.cfm">Presentations &amp; Articles</a></li>                                </ul>                            </li>                        </ul>                    </div>                                    <div class="col">                        <ul>                            <li>Application Development Support                                <ul>                                    <li><a href="dailymed/app-support.cfm">Resources</a>                                        <ul>                                            <li><a href="dailymed/app-support-web-services.cfm">Web Services</a></li>                                            <li><a href="dailymed/app-support-mapping-files.cfm">Mapping Files</a></li>                                        </ul>                                    </li>                                </ul>                            </li>                            <li><a href="dailymed/help.cfm">Help</a></li>                        </ul>                    </div>                </div>           		</noscript>                					<ul class="webview hasjs">						<li><a href="dailymed/index.cfm" title="Home">Home</a></li>						<li>													<a href="#" title="News">												News</a>							<ul class="sub-menu">								<li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>								<li><a href="dailymed/rss-updates.cfm">Get RSS News &amp; Updates</a></li>							</ul>						</li>						<li>																				<a href="dailymed/fda-drug-guidance.cfm" title="FDA Guidances &amp; Info">												FDA Guidances &amp; Info</a>													</li>						<li>													<a href="#" title="Structured Product Labeling (SPL) resources for industry professionals.">												NLM SPL Resources</a>														<ul class="sub-menu">								<li><a href="dailymed/spl-resources.cfm">Download Data</a>									<ul>										<li><a href="dailymed/spl-resources-all-drug-labels.cfm">All Drug Labels</a></li>										<li><a href="dailymed/spl-resources-all-indexing-files.cfm">All Indexing Files</a></li>										<li><a href="dailymed/spl-resources-all-mapping-files.cfm">All Mapping Files</a></li>									</ul>								</li>								<li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>								<li><a href="dailymed/spl-resources-presentations-articles.cfm">Presentations &amp; Articles</a></li>							</ul>						</li>						<li>													<a href="#" title="Application Development Support">												Application Development Support</a>							<ul class="sub-menu">								<li><a href="dailymed/app-support.cfm">Resources</a>									<ul>										<li><a href="dailymed/app-support-web-services.cfm">Web Services</a></li>																				<li><a href="dailymed/app-support-mapping-files.cfm">Mapping Files</a></li>									</ul>								</li>							</ul>						</li>									  						<li>													<a href="dailymed/help.cfm" title="Help">												Help</a></li>   					</ul>					<ul class="tabletview hasjs">						<li><a href="dailymed/advanced-search.cfm" title="Advanced Search">Advanced Search</a></li>						<li class="viewmore"><a href="#" title="View More">View More</a>							<ul>								<li><span>News</span>									<ul>										<li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>										<li><a href="dailymed/rss-updates.cfm">Get RSS News &amp; Updates</a></li>									</ul>								</li>								<li><span>Safety Reporting and Recalls</span>									<ul>										<li><a href="/www.accessdata.fda.gov/scripts/medwatch/" target="_blank">Report Adverse Events</a></li>										<li><a href="/www.fda.gov/Safety/Recalls" target="_blank">FDA Saftey Recalls</a></li>									</ul>								</li>								<li>									<a href="dailymed/fda-drug-guidance.cfm">FDA Guidances &amp; Information</a>								</li>																<li><span>NLM SPL Resources</span>									<ul>										<li><a href="dailymed/spl-resources.cfm">Download Data</a>											<ul>												<li><a href="dailymed/spl-resources-all-drug-labels.cfm">- All Drug Labels</a></li>												<li><a href="dailymed/spl-resources-all-indexing-files.cfm">- All Indexing Files</a></li>												<li><a href="dailymed/spl-resources-all-mapping-files.cfm">- All Mapping Files</a></li>											</ul>										</li>										<li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>										<li><a href="dailymed/spl-resources-presentations-articles.cfm">Presentations &amp; Articles</a></li>									</ul>								</li>   								<li><span>Application Development Support</span>									<ul>										<li><a href="dailymed/app-support.cfm">Resources</a>											<ul>												<li><a href="dailymed/app-support-web-services.cfm">- Web Services</a></li>																								<li><a href="dailymed/app-support-mapping-files.cfm">- Mapping Files</a></li>											</ul>										</li>									</ul>								</li>   								<li><a href="dailymed/help.cfm" title="Help">Help</a></li>   							</ul>						</li>						<li class="mobileview viewmore" tabindex="0"><a title="View More" href="#">More ways to search</a>							<ul>								<li tabindex="0"><a title="Browse Drug Classes" href="dailymed/browse-drug-classes.cfm">Browse Drug Classes</a></li>								<li tabindex="0"><a title="Label Archives" href="dailymed/archives/index.cfm">Label Archives</a></li>																<li tabindex="0"><a target="_blank" title="Tablet/Capsule ID Tool" href="http://pillbox.nlm.nih.gov/">Tablet/Capsule ID Tool</a></li>   							</ul>						</li>					</ul>										<ul class="mobileview hasjs">						<li><a href="dailymed/advanced-search.cfm" title="Advanced Search">Advanced Search</a></li>						<li tabindex="0" class="viewmore"><a href="#" title="View More">View More</a>							<ul>								<li tabindex="0"><a href="dailymed/browse-drug-classes.cfm" title="Browse Drug Classes">Browse Drug Classes</a></li>								<li tabindex="0"><a href="dailymed/archives/index.cfm" title="Label Archives">Label Archives</a></li>																<li tabindex="0"><a href="http://pillbox.nlm.nih.gov/" title="Tablet/Capsule ID Tool" target="_blank">Tablet/Capsule ID Tool</a></li>   							</ul>						</li>					</ul>				</nav>				<div class="divider_10 nomargin"></div>			</div>					</div>				<div class="divider"></div>	</div></header><div id="skip-main-content"></div>        <div class="container">             <div class="main-content">                <div class="header long">                    <div class="header-top">                            <h1>Label: <span class="long-title">FLUVASTATIN- fluvastatin sodium capsule <br></span></h1>                    </div>                                        <ul class="tools">                    	                        <li class="rss"><a href="#modal-label-rss" class="modal-open">Label RSS</a></li>                        <li class="share">Share                            <noscript>: JavaScript needed for Sharing tools</noscript>                            <!-- AddThis Button BEGIN -->                            <div class="addthis_toolbox addthis_default_style addthis_16x16_style">                                                                                                    	                                	            			        	                                                            <a class="email-share" href="mailto:?subject=DailyMed%20Web%20site%20information&amp;Body=I%20would%20like%20to%20share%20this%20page%20from%20the%20DailyMed%20website%20with%20you%3A%0A%0AFLUVASTATIN%2D%20Fluvastatin%20Sodium%20Capsule%0Ahttps%3A%2F%2Fdailymed%2Enlm%2Enih%2Egov%2Fdailymed%2FdrugInfo%2Ecfm%3Fsetid%3Daad8b373%2D0aec%2D4efb%2D8e61%2D3d8114b31127%0A%0ADailyMed%20is%20a%20site%20provided%20by%20The%20National%20Library%20of%20Medicine%20%28NLM%29%20and%20is%20the%20official%20provider%20of%20FDA%20drug%20label%20information%20%28package%20inserts%29%2E" title="Share by Email"></a>                                <a class="addthis_button_facebook"></a>                                <a class="addthis_button_twitter"></a>                                                                <a class="at300bs at15nc at15t_compact reveal" title="Bookmark &amp; Share" href="/www.addthis.com/bookmark.php?pub=DailyMed&amp;title=DailyMed" target="_blank" style="display: block;">                                    <span style="left: -9999px; position: absolute;">Bookmark &amp; Share</span><img style="width:17px" src="/dailymed/images/addthis-image.jpg"></img>                                </a>                            </div>                            <script type="text/javascript">var addthis_config = {"data_track_addressbar":false};</script>                            <script type="text/javascript" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-542300cc2097c8b5" ></script>                             <!-- AddThis Button END -->                                                    </li>                    </ul>                  </div>                <div class="four columns sidebar" id="leftmenu">                    <section>                        <article>                                                        <div class="w-photos">                            	                                                                <div class="mod drug-photos">                                <h2><a>View Package Photos</a></h2>                                <ul>                                    <li>                                                                               <ul>                                                                                                                        	                                            	 <li class="img package-photo"><a href="image.cfm?type=img&name=acd656cf-3edc-499c-9630-17ac45753572-06.jpg&setid=aad8b373-0aec-4efb-8e61-3d8114b31127" class="thumbnail" title="Package Photo" data-photo-type="package" data-slideorder="0">                                                 	<img id="zoom_1" title="Package Photo" alt="Package Photo"                                                     data-zoom-image="image.cfm?type=img&name=acd656cf-3edc-499c-9630-17ac45753572-06.jpg&setid=aad8b373-0aec-4efb-8e61-3d8114b31127" src="image.cfm?type=img&name=acd656cf-3edc-499c-9630-17ac45753572-06.jpg&setid=aad8b373-0aec-4efb-8e61-3d8114b31127" data-photo-type="package">                                                 	<span class="enlarge"></span>                                                    </a></li>                                                                                             											                                                                                	                                            	 <li class="img package-photo"><a href="image.cfm?type=img&name=acd656cf-3edc-499c-9630-17ac45753572-07.jpg&setid=aad8b373-0aec-4efb-8e61-3d8114b31127" class="thumbnail" title="Package Photo" data-photo-type="package" data-slideorder="1">                                                 	<img id="zoom_2" title="Package Photo" alt="Package Photo"                                                     data-zoom-image="image.cfm?type=img&name=acd656cf-3edc-499c-9630-17ac45753572-07.jpg&setid=aad8b373-0aec-4efb-8e61-3d8114b31127" src="image.cfm?type=img&name=acd656cf-3edc-499c-9630-17ac45753572-07.jpg&setid=aad8b373-0aec-4efb-8e61-3d8114b31127" data-photo-type="package">                                                 	<span class="enlarge"></span>                                                    </a></li>                                                                                             											                                                                                </ul>                                    </li>                                </ul>								                                </div>            								                                                                                                <div class="mod drug-photos">                                <h2><a>View Drug Photos</a></h2>                                                                    <strong><a class="tip" rel="tooltip" title="NDC (National Drug Code) - Each drug product is assigned this unique number which can be found on the drug's outer packaging." href="#">NDC Codes:</a></strong>                                        <ul>                                        <li>                                            <ul>                                                                                                                                                                                                                                                                                                                                                                                    	                                                                                                                                                                                                                                                                                                                                                                                                                                                                    <li class="img drug-photo">                                                            	<p>0093-7443-56</p>                                                                                                                                                                                            	<a href="/rximage.nlm.nih.gov/image/images/gallery/original/00093-7443-56_NLMIMAGE10_052702B8.jpg"                                                                  class="thumbnail"                                                                  title="fluvastatin&#x20;40&#x20;MG&#x20;Oral&#x20;Capsule"                                                                 data-slideorder="2"                                                                 data-ndccode="0093-7443-56"                                                                 data-standardname="fluvastatin&#x20;40&#x20;MG&#x20;Oral&#x20;Capsule"                                                                 data-shape="CAPSULE"                                                                 data-size="19mm"                                                                 data-color="YELLOW,&#x20;PINK"                                                                 data-scored="1"                                                                 data-imprint="TEVA&#x3b;7443"                                                                 data-photo-type="drug" >                                                                	<img id="zoom_3"                                                                         title="fluvastatin&#x20;40&#x20;MG&#x20;Oral&#x20;Capsule"                                                                         alt="fluvastatin&#x20;40&#x20;MG&#x20;Oral&#x20;Capsule"                                                                         data-zoom-image="//rximage.nlm.nih.gov/image/images/gallery/original/00093-7443-56_NLMIMAGE10_052702B8.jpg"                                                                         src="//rximage.nlm.nih.gov/image/images/gallery/original/00093-7443-56_NLMIMAGE10_052702B8.jpg"                                                                         />                                                                    <span class="enlarge"></span>                                                                </a>                                                             </li>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    	                                                                                                                                                                                                                                                                                                                                                                                                                                                                    <li class="img drug-photo">                                                            	<p>0093-7442-56</p>                                                                                                                                                                                            	<a href="/rximage.nlm.nih.gov/image/images/gallery/original/00093-7442-56_NLMIMAGE10_30271848.jpg"                                                                  class="thumbnail"                                                                  title="fluvastatin&#x20;20&#x20;MG&#x20;Oral&#x20;Capsule"                                                                 data-slideorder="3"                                                                 data-ndccode="0093-7442-56"                                                                 data-standardname="fluvastatin&#x20;20&#x20;MG&#x20;Oral&#x20;Capsule"                                                                 data-shape="CAPSULE"                                                                 data-size="16mm"                                                                 data-color="WHITE,&#x20;PINK"                                                                 data-scored="1"                                                                 data-imprint="TEVA&#x3b;7442"                                                                 data-photo-type="drug" >                                                                	<img id="zoom_4"                                                                         title="fluvastatin&#x20;20&#x20;MG&#x20;Oral&#x20;Capsule"                                                                         alt="fluvastatin&#x20;20&#x20;MG&#x20;Oral&#x20;Capsule"                                                                         data-zoom-image="//rximage.nlm.nih.gov/image/images/gallery/original/00093-7442-56_NLMIMAGE10_30271848.jpg"                                                                         src="//rximage.nlm.nih.gov/image/images/gallery/original/00093-7442-56_NLMIMAGE10_30271848.jpg"                                                                         />                                                                    <span class="enlarge"></span>                                                                </a>                                                             </li>                                                                                                                                                                                                                                                            </ul>                                        </li>                                    </ul>                                	                                </div>                                                            </div>                            <div class="mod-wrap">                                <div class="mod blue-list page-jump">                                    <h2><a href="#drug-information">Drug Label Info</a></h2>                                </div>                                                                <div class="mod blue-list orange">                                                                                                                                                                                                                                                                                                                                                                            <h2><a href="#">Safety</a></h2>                                    <ul>                                                                                                                                                                    <li>                                                <a href="/www.accessdata.fda.gov/scripts/medwatch/ " target="_blank">Report Adverse Events</a>                                            </li>                                            <li><a href="http://www.fda.gov/Safety/Recalls/" target="_blank">FDA Safety Recalls</a></li>                                            <li>                                                <a href="http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@or+%28@na+%22FLUVASTATIN%22+%29" target="_blank">Presence in Breast Milk</a>                                            </li>                                                                            </ul>                                </div>                                <div class="mod blue-list">                                    <h2><a href="#">Related Resources</a></h2>                                    <ul>                                                                                                                            <li>                                                <a href="/vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v:project=medlineplus&query=FLUVASTATIN" target="_blank">Medline Plus</a>                                            </li>                                                                                <li>                                            <a href="/www.clinicaltrials.gov/ct/search?submit=Search&term=FLUVASTATIN" target="blank">Clinical Trials</a>                                        </li>                                                                                    <li>                                                <a href="#" id="pubmed-menu">PubMed</a>                                            	    											                                                                                                <ul>                                                    <li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=FLUVASTATIN[All Fields]" title="Link opens new window for All Citations" target="pubmed">All Citations</a>                                                    </li>                                					<li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=FLUVASTATIN/AE" title="Link opens new window for Adverse Effects" target="pubmed">Adverse Effects</a>                                                    </li>                                					<li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=FLUVASTATIN/TU"  title="Link opens new window for Therapeutic Use" target="pubmed">Therapeutic Use</a>                                                    </li>                                					<li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=FLUVASTATIN/PD" title="Link opens new window for Pharmacology" target="pubmed">Pharmacology</a>                                                    </li>                                					<li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=FLUVASTATIN[All Fields] AND Clinical Trial[ptyp]" title="Link opens new window for Clinical Trials" target="pubmed">Clinical Trials</a>                                                    </li>                                                </ul>                                            </li>                                            <li>                                                <a href="http://www.drugbank.ca/search?utf8=%E2%9C%93&query=APRD00346&search_type=drugs&button=" target="_blank">Biochemical Data Summary</a>                                            </li>                                                                            </ul>                                </div>                                <div class="mod blue-list">                                    <h2><a href="#">More Info For This Drug</a></h2>                                    <ul>                                    	                                        <li><a href="#modal-label-archives" class="modal-open">View Label Archives</a></li>                                        <li><a href="#modal-rx-norm" class="modal-open">RxNorm</a></li>                                                                                <li><a href="#modal-label-rss" class="modal-open">Get Label RSS Feed</a></li>                                    </ul>                                </div>                                                            </div>                        </article>                    </section>                </div>                               <div class="content-wide">                        <article>                            <ul class="drug-information">                            	                                                                <li>                                <strong><a class="tip" rel="tooltip" title="NDC (National Drug Code) - Each drug product is assigned this unique number which can be found on the drug's outer packaging." href="#">NDC Code(s):</a></strong> <span id="item-code-s">                                                                                                	                                    0093-7442-01,                                                                                                                                        	                                    0093-7442-56,                                                                                                                                        	                                    0093-7443-01,                                                                                                                                        	                                    0093-7443-56                                                                                                                                                                        								</li>                                <li>                                                                                                                                                                <li><strong>Packager: </strong>Teva Pharmaceuticals USA Inc</li>                                						    	    																																			    																	    	    	                             		       	                                                                                                                                                           </ul>                                                        <ul class="drug-information">                            	                                <li><strong>Category:</strong>                                 	                                    	<span id="category" class="orangetext">                                                                            	HUMAN PRESCRIPTION DRUG LABEL</span></li>                                                                    <li><strong>DEA Schedule:</strong> <span id="dea-schedule">                                                                        	None                                                                        </span></li>                                                                    <li><strong>Marketing Status:</strong> <span id="marketing-status">Abbreviated New Drug Application</span></li>								                            </ul>							                                    <div id="drug-information" class="toggle">                                                                                    <h2><a id="druglabel"></a>Drug Label Information</h2>                                                 <p class="date">Updated                                                  	                                                    	11/13                                                                                                     </p>                                                   <p class="orangetext">If you are a consumer or patient please visit <a href="dailymed/drugInfo.cfm?setid=aad8b373-0aec-4efb-8e61-3d8114b31127&audience=consumer">this version.</a></p>                                                                                                   <ul class="tools">                                                    <li class="download">Download DRUG LABEL INFO: <a class="pdf" href="dailymed/getFile.cfm?setid=aad8b373-0aec-4efb-8e61-3d8114b31127&amp;type=pdf&amp;name=aad8b373-0aec-4efb-8e61-3d8114b31127" target="_blank">PDF</a>                                                    	<a class="xml" href="dailymed/getFile.cfm?setid=aad8b373-0aec-4efb-8e61-3d8114b31127&amp;type=zip&amp;name=FLUVASTATIN">XML</a>                                                    </li>                                                                                                                                                            <li class="print">                                                        <a href="dailymed/fda/fdaDrugXsl.cfm?setid=aad8b373-0aec-4efb-8e61-3d8114b31127&amp;type=display" target="_blank">Print Drug Label Info</a>                                                    </li>                                                                                                    </ul>                                                                                                  <div class="drug-label-sections">                                                   <div class="control-nav show-js">                                            <a class="open-all" href="#">View All Sections</a><a class="close-all" href="#">Close All Sections</a>                                        </div>                                                                        <ul>                                                                                        	                                                <li><a href="#">HIGHLIGHTS OF PRESCRIBING INFORMATION</a> <div id="Highlights" class=" Highlights toggle-content closed">    <div class="HighlightsDisclaimer">   These highlights do not include all the information needed to use fluvastatin capsules USP safely and effectively. See full prescribing information for fluvastatin capsules USP.    <br />FLUVASTATIN capsules USP for oral use   <br />Initial U.S. Approval: 1993   </div>   <div></div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>INDICATIONS AND USAGE</span> </h1>    <div>     <p class="Highlighta">Fluvastatin capsules USP are an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: </p>     <ul>      <li>Reduce elevated TC, LDL-C, Apo B, and TG, and to increase HDL-C in adult patients with primary hypercholesterolemia and mixed dyslipidemia (<a href="#i4i_section_id_58f3ddbe-a9f1-46f0-ac63-c88e7fb34d44">1.1</a>) </li>      <li>Reduce elevated TC, LDL-C, and Apo B levels in boys and post-menarchal girls, 10 to 16 years of age, with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy (<a href="#i4i_section_id_58f3ddbe-a9f1-46f0-ac63-c88e7fb34d44">1.1</a>) </li>      <li>Reduce the risk of undergoing revascularization procedures in patients with clinically evident CHD (<a href="#i4i_section_id_5f2eb94b-4cdf-4517-9ad8-298e02fe9677">1.2</a>) </li>      <li>Slow the progression of atherosclerosis in patients with CHD (<a href="#i4i_section_id_5f2eb94b-4cdf-4517-9ad8-298e02fe9677">1.2</a>)</li>     </ul>     <p class="Highlighta">Limitations of Use: </p>     <ul>      <li>Fluvastatin capsules USP have not been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL, or IDL (i.e., hyperlipoproteinemia Types I, III, IV, or V). (<a href="#i4i_section_id_d7198c78-f82a-490b-902e-203cf2892af6">1.3</a>) </li>     </ul>    </div>    <div></div>    <div></div>    <div></div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>DOSAGE AND ADMINISTRATION</span> </h1>    <div>     <ul>      <li>Dose range: 20 mg to 80 mg/day (<a href="#i4i_section_id_f24513f7-13a1-450c-b277-7823c2303d14">2.1</a>) </li>      <li>Fluvastatin capsules USP can be taken with or without food. (<a href="#i4i_section_id_f24513f7-13a1-450c-b277-7823c2303d14">2.1</a>) </li>      <li>Do not open fluvastatin capsules USP prior to administration (<a href="#i4i_section_id_f24513f7-13a1-450c-b277-7823c2303d14">2.1</a>) </li>      <li>Adults: the recommended starting dose is 40 mg to 80 mg (administered as one fluvastatin capsule USP, 40 mg twice daily) (<a href="#i4i_section_id_b8e3f439-b516-4846-a98d-167d87e040b2">2.2</a>) </li>      <li>Do not take two fluvastatin capsules USP, 40 mg at one time </li>      <li>Children with heterozygous familial hypercholesterolemia (ages 10 to 16, inclusive): the recommended starting dose is fluvastatin capsule USP, 20 mg once daily (<a href="#i4i_section_id_2f9bb971-1f1c-4c62-b1a6-0df3aca4ab69">2.3</a>)</li>     </ul>    </div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>DOSAGE FORMS AND STRENGTHS</span> </h1>    <div>     <p class="Highlighta">Fluvastatin capsules USP: 20 mg, 40 mg (<a href="#i4i_dosage_form_strength_id_c88f5f23-040e-4cc4-b901-6eaef0119be9">3</a>) </p>    </div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>CONTRAINDICATIONS</span> </h1>    <div>     <ul>      <li>Hypersensitivity to any component of this medication (<a href="#i4i_contraindications_id_386b27c8-1942-472b-a659-de72694c59b7">4</a>) </li>      <li>Active liver disease or unexplained, persistent elevations in serum transaminases (<a href="#i4i_contraindications_id_386b27c8-1942-472b-a659-de72694c59b7">4</a>, <a href="#i4i_section_id_8af78cea-813b-44db-ada4-217115af1f2c">5.2</a>) </li>      <li>Women who are pregnant or may become pregnant (<a href="#i4i_contraindications_id_386b27c8-1942-472b-a659-de72694c59b7">4</a>, <a href="#i4i_pregnancy_id_f55b8c53-f167-4135-8643-9a208663e558">8.1</a>)</li>      <li>Nursing mothers (<a href="#i4i_contraindications_id_386b27c8-1942-472b-a659-de72694c59b7">4</a>, <a href="#i4i_nursing_mothers_id_da971182-d2fc-4775-b59f-98d27dd54a66">8.3</a>) </li>     </ul>    </div>    <div></div>    <div></div>    <div></div>    <div></div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>WARNINGS AND PRECAUTIONS</span> </h1>    <div>     <ul>      <li> <span class="Bold">Skeletal muscle effects (e.g., myopathy and rhabdomyolysis):</span> Risks increase with advanced age ( 65), uncontrolled hypothyroidism, renal impairment, and combination use with cyclosporine,or gemfibrozil. Advise patients to promptly report to their physician unexplained and/or persistent muscle pain, tenderness, or weakness and discontinue fluvastatin if myopathy is diagnosed or suspected. (<a href="#i4i_section_id_e04b0745-ab1b-4bfc-b72e-ea8713c0a247">5.1</a>, <a href="#i4i_geriatric_use_id_9ad69df3-88a4-4138-ab65-f2e0e58c8eed">8.5</a>, <a href="#i4i_section_id_4dbf5df9-7f17-4a26-b1fc-e95acef063d3">8.7</a>)</li>      <li>Patients should be advised to report promptly any symptoms of myopathy. Fluvastatin capsules therapy should be discontinued if myopathy is diagnosed or suspected (<a href="#i4i_section_id_e04b0745-ab1b-4bfc-b72e-ea8713c0a247">5.1</a>) </li>      <li> <span class="Bold">Liver enzyme abnormalities:</span> Persistent elevations in hepatic transaminases can occur. Check liver enzyme tests before initiating therapy and as clinically indicated thereafter (<a href="#i4i_section_id_8af78cea-813b-44db-ada4-217115af1f2c">5.2</a>) </li>     </ul>    </div>    <div></div>    <div></div>    <div></div>    <div></div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>ADVERSE REACTIONS</span> </h1>    <div>     <p class="Highlighta">Most frequent adverse reactions (rate  2% and &gt; placebo) are: headache, dyspepsia, myalgia, abdominal pain and nausea (<a href="#i4i_section_id_8f14ec0d-1282-4d95-acbb-2f9e4f64dae2">6.1</a>) </p>     <p class="Highlighta"> <span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact TEVA USA, PHARMACOVIGILANCE at 1-866-832-8537 or drug.safety@tevapharm.com; or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. </span> </p>    </div>    <div></div>    <div></div>    <div></div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>DRUG INTERACTIONS</span> </h1>    <div>     <ul>      <li> <span class="Bold">Cyclosporine:</span> Combination increases fluvastatin exposure. Limit fluvastatin dose to 20 mg (<a href="#i4i_section_id_bea39dab-3e7c-4d1e-95dc-46ab6e055043">2.4</a>, <a href="#i4i_section_id_1cd8ed8a-19fc-4b25-afa1-d811fff09609">7.1</a>) </li>      <li> <span class="Bold">Fluconazole:</span> Combination increases fluvastatin exposure. Limit fluvastatin dose to 20 mg (<a href="#i4i_section_id_78318e06-66c0-482f-bd31-077199beff44">2.5</a>, <a href="#i4i_section_id_7f42ffc0-b116-4c0d-8b97-2214c2a32d99">7.2</a>) </li>      <li> <span class="Bold">Concomitant lipid-lowering therapies:</span> Use with fibrates or lipid-modifying doses ( 1 g/day) of niacin increases the risk of adverse skeletal muscle effects. Caution should be used when prescribing with fluvastatin (<a href="#i4i_section_id_e04b0745-ab1b-4bfc-b72e-ea8713c0a247">5.1</a>, <a href="#i4i_section_id_ada36022-3fd3-4ac0-9d35-1ece37c1e828">7.3</a>, <a href="#i4i_section_id_b8b8fb97-7867-46b7-a9dc-fe7cf8c4cb5c">7.4</a>) </li>      <li> <span class="Bold">Glyburide:</span> Monitor blood glucose levels when fluvastatin dose is changed (<a href="#i4i_interactions_id_25d02351-69fd-4e29-9276-8e0b77bc6752">7</a>) </li>      <li> <span class="Bold">Phenytoin: </span>Monitor plasma phenytoin levels when fluvastatin treatment is initiated or when the dosage is changed (<a href="#i4i_interactions_id_25d02351-69fd-4e29-9276-8e0b77bc6752">7</a>) </li>      <li> <span class="Bold">Warfarin and coumarin derivates:</span> Monitor prothrombin times when fluvastatin coadministration is initiated, discontinued, or the dosage changed (<a href="#i4i_interactions_id_25d02351-69fd-4e29-9276-8e0b77bc6752">7</a>) </li>     </ul>    </div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>   </div>   <div>    <div>     <div>      <div></div>     </div>    </div>    <div></div>    <div></div>    <div></div>    <div></div>   </div>   <div></div>   <div></div>   <div>    <div></div>    <div></div>   </div>   <div>    <div></div>   </div>   <div>    <div></div>    <div></div>    <div></div>   </div>   <div></div>   <div>    <div></div>   </div>   <div>    <div></div>    <div></div>    <div></div>    <div></div>   </div>   <div></div>   <div>    <div></div>   </div>   <div>    <div></div>   </div>   <p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>   <p class="HighlightsRevision">Revised: 11/2013</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">FULL PRESCRIBING INFORMATION: CONTENTS*</a> <div id="Index" class=" Index toggle-content closed">    <h1> <a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a> </h1>   <h2> <a href="#section-1.1" class="toc">1.1 Hypercholesterolemia (Heterozygous Familial and Nonfamilial) and Mixed Dyslipidemia </a> </h2>   <h2> <a href="#section-1.2" class="toc">1.2 Secondary Prevention of Cardiovascular Disease </a> </h2>   <h2> <a href="#section-1.3" class="toc">1.3 Limitations of Use</a> </h2>   <h1> <a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a> </h1>   <h2> <a href="#section-2.1" class="toc">2.1 General Dosing Information</a> </h2>   <h2> <a href="#section-2.2" class="toc">2.2 Adult Patients With Hypercholesterolemia (Heterozygous Familial and Nonfamilial) and Mixed Dyslipidemia </a> </h2>   <h2> <a href="#section-2.3" class="toc">2.3 Pediatric Patients (10 to 16 Years of Age) With Heterozygous Familial Hypercholesterolemia</a> </h2>   <h2> <a href="#section-2.4" class="toc">2.4 Use With Cyclosporine</a> </h2>   <h2> <a href="#section-2.5" class="toc">2.5 Use With Fluconazole</a> </h2>   <h1> <a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a> </h1>   <h1> <a href="#section-4" class="toc">4 CONTRAINDICATIONS</a> </h1>   <h2> <a href="#section-4.1" class="toc">4.1 Hypersensitivity to any Component of This Medication</a> </h2>   <h2> <a href="#section-4.2" class="toc">4.2 Active Liver Disease</a> </h2>   <h2> <a href="#section-4.3" class="toc">4.3 Pregnancy</a> </h2>   <h2> <a href="#section-4.4" class="toc">4.4 Nursing Mothers</a> </h2>   <h1> <a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a> </h1>   <h2> <a href="#section-5.1" class="toc">5.1 Skeletal Muscle</a> </h2>   <h2> <a href="#section-5.2" class="toc">5.2 Liver Enzymes</a> </h2>   <h2> <a href="#section-5.3" class="toc">5.3 Endocrine Effects</a> </h2>   <h2> <a href="#section-5.4" class="toc">5.4 CNS Toxicity</a> </h2>   <h1> <a href="#section-6" class="toc">6 ADVERSE REACTIONS</a> </h1>   <h2> <a href="#section-6.1" class="toc">6.1 Clinical Studies Experience in Adult Patients</a> </h2>   <h2> <a href="#section-6.2" class="toc">6.2 Clinical Studies Experience in Pediatric Patients</a> </h2>   <h2> <a href="#section-6.3" class="toc">6.3 Postmarketing Experience</a> </h2>   <h1> <a href="#section-7" class="toc">7 DRUG INTERACTIONS</a> </h1>   <h2> <a href="#section-7.1" class="toc">7.1 Cyclosporine</a> </h2>   <h2> <a href="#section-7.2" class="toc">7.2 Fluconazole</a> </h2>   <h2> <a href="#section-7.3" class="toc">7.3 Gemfibrozil</a> </h2>   <h2> <a href="#section-7.4" class="toc">7.4 Other Fibrates</a> </h2>   <h2> <a href="#section-7.5" class="toc">7.5 Niacin</a> </h2>   <h2> <a href="#section-7.6" class="toc">7.6 Glyburide</a> </h2>   <h2> <a href="#section-7.7" class="toc">7.7 Phenytoin</a> </h2>   <h2> <a href="#section-7.8" class="toc">7.8 Warfarin</a> </h2>   <h2> <a href="#section-7.9" class="toc">7.9 Colchicine </a> </h2>   <h1> <a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a> </h1>   <h2> <a href="#section-8.1" class="toc">8.1 Pregnancy</a> </h2>   <h2> <a href="#section-8.2" class="toc">8.3 Nursing Mothers</a> </h2>   <h2> <a href="#section-8.3" class="toc">8.4 Pediatric Use</a> </h2>   <h2> <a href="#section-8.4" class="toc">8.5 Geriatric Use</a> </h2>   <h2> <a href="#section-8.5" class="toc">8.6 Hepatic Impairment</a> </h2>   <h2> <a href="#section-8.6" class="toc">8.7 Renal Impairment</a> </h2>   <h1> <a href="#section-9" class="toc">10 OVERDOSAGE</a> </h1>   <h1> <a href="#section-10" class="toc">11 DESCRIPTION</a> </h1>   <h1> <a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a> </h1>   <h2> <a href="#section-11.1" class="toc">12.1 Mechanism of Action</a> </h2>   <h2> <a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a> </h2>   <h1> <a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a> </h1>   <h2> <a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a> </h2>   <h1> <a href="#section-13" class="toc">14 CLINICAL STUDIES</a> </h1>   <h2> <a href="#section-13.1" class="toc">14.1 Hypercholesterolemia (Heterozygous Familial and Nonfamilial) and Mixed Dyslipidemia</a> </h2>   <h2> <a href="#section-13.2" class="toc">14.2 Heterozygous Familial Hypercholesterolemia in Pediatric Patients</a> </h2>   <h2> <a href="#section-13.3" class="toc">14.3 Secondary Prevention of Cardiovascular Disease</a> </h2>   <h1> <a href="#section-14" class="toc">15 REFERENCES</a> </h1>   <h1> <a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a> </h1>   <h2> <a href="#section-15.1" class="toc">Store and Dispense</a> </h2>   <h1> <a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a> </h1>   <h2> <a href="#section-16.1" class="toc">17.1 Muscle Pain</a> </h2>   <h2> <a href="#section-16.2" class="toc">17.2 Liver Enzymes</a> </h2>   <h2> <a href="#section-16.3" class="toc">17.3 Pregnancy</a> </h2>   <h2> <a href="#section-16.4" class="toc">17.4 Breastfeeding</a> </h2>   <h2> <a href="#section-18.1" class="toc">Fluvastatin Capsules USP 20 mg 100s Label Text</a> </h2>   <h2> <a href="#section-19.1" class="toc">Fluvastatin Capsules USP 40 mg 100s Label Text</a> </h2>   <dl class="Footnote">    <dt>     <a name="footnote-content" href="#footnote-reference-content">*</a>    </dt>    <dd>    Sections or subsections omitted from the full prescribing information are not listed.   </dd>   </dl>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">1 INDICATIONS AND USAGE</a> <div class="Section toggle-content closed" data-sectioncode="34067-9">   <a name="i4i_indications_id_b9514fe5-5ea4-473a-b828-cfa67d3b1aba"></a>  <a name="section-1"></a>   <p></p>    <p class="First">Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other non-pharmacologic measures alone has been inadequate. </p>   <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_58f3ddbe-a9f1-46f0-ac63-c88e7fb34d44"></a>   <a name="section-1.1"></a>    <p></p>    <h2>1.1 Hypercholesterolemia (Heterozygous Familial and Nonfamilial) and Mixed Dyslipidemia </h2>    <p class="First">Fluvastatin capsules USP are indicated </p>    <ul>     <li>as an adjunct to diet to reduce elevated total cholesterol (Total-C), low-density lipoprotein cholesterol (LDL-C), triglyceride (TG) and apolipoprotein B (Apo B) levels, and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Type IIa and IIb). </li>     <li>as an adjunct to diet to reduce Total-C, LDL-C, and Apo B levels in adolescent boys and adolescent girls who are at least one year post-menarche, 10 to 16 years of age, with heterozygous familial hypercholesterolemia and the following findings are present:      <ul>       <li>LDL-C remains  190 mg/dL or </li>       <li>LDL-C remains  160 mg/dL and:        <ul>         <li>there is a positive family history of premature cardiovascular disease or </li>         <li>two or more other cardiovascular disease risk factors are present </li>        </ul> </li>      </ul> </li>    </ul>    <p>The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature CVD is summarized below. </p>    <a name="id_ec7297ec-a5fd-4a12-bddf-63502e28d73d"></a>    <div class="scrollingtable">    <table border="single" width="443">      <colgroup>      <col width="33.3%" />       <col width="33.3%" />       <col width="33.3%" />      </colgroup>     <tbody class="Headless">       <tr class="First">        <td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Category</span></td>       <td class="Botrule Rrule" align="left" valign="top"><span class="Bold">Total-C (mg/dL)</span></td>       <td class="Botrule Rrule" align="left" valign="top"><span class="Bold">LDL-C (mg/dL)</span></td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="left" valign="top">Acceptable</td>       <td class="Botrule Rrule" align="left" valign="top">&lt; 170</td>       <td class="Botrule Rrule" align="left" valign="top">&lt; 110</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="left" valign="top">Borderline</td>       <td class="Botrule Rrule" align="left" valign="top">170 to 199</td>       <td class="Botrule Rrule" align="left" valign="top">110 to 129</td>       </tr>       <tr class="Last">        <td class="Botrule Lrule Rrule" align="left" valign="top">High</td>       <td class="Rrule" align="left" valign="top"> 200</td>       <td class="Botrule Rrule" align="left" valign="top"> 130</td>       </tr>      </tbody>     </table>   </div>    <p>Children treated with fluvastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult treatment goals. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_5f2eb94b-4cdf-4517-9ad8-298e02fe9677"></a>   <a name="section-1.2"></a>    <p></p>    <h2>1.2 Secondary Prevention of Cardiovascular Disease </h2>    <p class="First">In patients with clinically evident CHD, fluvastatin capsules USP are indicated to:</p>    <ul>     <li>reduce the risk of undergoing coronary revascularization procedures</li>     <li>slow the progression of coronary atherosclerosis </li>    </ul>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_d7198c78-f82a-490b-902e-203cf2892af6"></a>   <a name="section-1.3"></a>    <p></p>    <h2>1.3 Limitations of Use</h2>    <p class="First">Fluvastatin capsules USP have not been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL, or IDL (i.e., hyperlipoproteinemia Types I, III, IV, or V). </p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">2 DOSAGE AND ADMINISTRATION</a> <div class="Section toggle-content closed" data-sectioncode="34068-7">   <a name="i4i_dosage_admin_id_0e871e12-e843-4361-9579-7763e877f9bf"></a>  <a name="section-2"></a>   <p></p>    <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_f24513f7-13a1-450c-b277-7823c2303d14"></a>   <a name="section-2.1"></a>    <p></p>    <h2>2.1 General Dosing Information</h2>    <p class="First">Dose range: 20 mg to 80 mg/day. </p>    <p>Fluvastatin capsules USP can be administered orally as a single dose, with or without food. </p>    <p>Do not open fluvastatin capsules USP prior to administration. </p>    <p>Do not take two fluvastatin capsules USP, 40 mg at one time. </p>    <p>Since the maximal effect of a given dose is seen within 4 weeks, periodic lipid determinations should be performed at this time and dosage adjusted according to the patients response to therapy and established treatment guidelines. </p>    <p>For patients requiring LDL-C reduction to a goal of  25%, the recommended starting dose is 40 mg as one capsule in the evening, or 80 mg in divided doses of the 40 mg capsule given twice daily. For patients requiring LDL-C reduction to a goal of &lt; 25% a starting dose of 20 mg may be used. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_b8e3f439-b516-4846-a98d-167d87e040b2"></a>   <a name="section-2.2"></a>    <p></p>    <h2>2.2 Adult Patients With Hypercholesterolemia (Heterozygous Familial and Nonfamilial) and Mixed Dyslipidemia </h2>    <p class="First">Adult patients can be started on fluvastatin capsules USP. The recommended starting dose for fluvastatin capsules USP is one 40 mg capsule in the evening, or one fluvastatin capsule USP, 40 mg twice daily. Do not take two fluvastatin capsules USP, 40 mg at one time. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_2f9bb971-1f1c-4c62-b1a6-0df3aca4ab69"></a>   <a name="section-2.3"></a>    <p></p>    <h2>2.3 Pediatric Patients (10 to 16 Years of Age) With Heterozygous Familial Hypercholesterolemia</h2>    <p class="First">The recommended starting dose is one fluvastatin capsule USP, 20 mg. Dose adjustments, up to a maximum daily dose administered as fluvastatin capsules USP, 40 mg twice daily should be made at 6 week intervals. Doses should be individualized according to the goal of therapy [<span class="Italics">see NCEP Pediatric Panel Guidelines and CLINICAL STUDIES (<a href="#i4i_clinical_studies_id_178aed6d-69ac-4787-8bdf-67ed85e0a728">14</a>)</span>]<span class="Sup">1</span>. </p>    <p> <span class="Sup">1 </span>National Cholesterol Education Program (NCEP): Highlights of the Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. <span class="Italics">Pediatrics. </span>89(3):495-501. 1992. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_bea39dab-3e7c-4d1e-95dc-46ab6e055043"></a>   <a name="section-2.4"></a>    <p></p>    <h2>2.4 Use With Cyclosporine</h2>    <p class="First">Do not exceed a dose of 20 mg b.i.d. fluvastatin capsules USP in patients taking cyclosporine [<span class="Italics">see Drug Interactions (<a href="#i4i_section_id_1cd8ed8a-19fc-4b25-afa1-d811fff09609">7.1</a>)</span>].</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_78318e06-66c0-482f-bd31-077199beff44"></a>   <a name="section-2.5"></a>    <p></p>    <h2>2.5 Use With Fluconazole</h2>    <p class="First">Do not exceed a dose of 20 mg b.i.d. fluvastatin capsules USP in patients taking fluconazole [<span class="Italics">see Drug Interactions (<a href="#i4i_section_id_7f42ffc0-b116-4c0d-8b97-2214c2a32d99">7.2</a>)</span>]. </p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">3 DOSAGE FORMS AND STRENGTHS</a> <div class="Section toggle-content closed" data-sectioncode="43678-2">   <a name="i4i_dosage_form_strength_id_c88f5f23-040e-4cc4-b901-6eaef0119be9"></a>  <a name="section-3"></a>   <p></p>    <ul>    <li>20 mg are hard gelatin capsules with ivory opaque body and pink opaque cap, filled with an off-white to yellowish powder with small agglomerates. Body imprinted with TEVA and cap imprinted with 7442. </li>    <li>40 mg are hard gelatin capsules with yellow opaque body and pink opaque cap, filled with an off-white to yellowish powder with small agglomerates. Body imprinted with TEVA and cap imprinted with 7443. </li>   </ul>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">4 CONTRAINDICATIONS</a> <div class="Section toggle-content closed" data-sectioncode="34070-3">   <a name="i4i_contraindications_id_386b27c8-1942-472b-a659-de72694c59b7"></a>  <a name="section-4"></a>   <p></p>    <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_16626fd1-b0a0-4a37-9203-5a7b2e43ad0c"></a>   <a name="section-4.1"></a>    <p></p>    <h2>4.1 Hypersensitivity to any Component of This Medication</h2>    <p class="First">Fluvastatin capsules are contraindicated in patients with hypersensitivity to any component of this medication. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_d3359bf9-0b2a-4c33-b30c-54c05079911f"></a>   <a name="section-4.2"></a>    <p></p>    <h2>4.2 Active Liver Disease</h2>    <p class="First">Fluvastatin capsules are contraindicated in patients with active liver disease or unexplained, persistent elevations in serum transaminases [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_8af78cea-813b-44db-ada4-217115af1f2c">5.2</a>)</span>]. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_c7187874-ee5f-4abc-9927-d877965430eb"></a>   <a name="section-4.3"></a>    <p></p>    <h2>4.3 Pregnancy</h2>    <p class="First">Fluvastatin capsules are contraindicated in women who are pregnant or may become pregnant.&nbsp; Serum cholesterol and triglycerides increase during normal pregnancy, and cholesterol or cholesterol derivatives are essential for fetal development. Fluvastatin capsules may cause fetal harm when administered to pregnant women. Atherosclerosis is a chronic process and the discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hypercholesterolemia. </p>    <p>Fluvastatin capsules should be administered to women of childbearing age only when such patients are highly unlikely to conceive and have been informed of the potential hazards. If the patient becomes pregnant while taking this drug, fluvastatin capsules should be discontinued and the patient should be apprised of the potential hazard to the fetus [<span class="Italics">see Use in Specific Populations (<a href="#i4i_pregnancy_id_f55b8c53-f167-4135-8643-9a208663e558">8.1</a>)</span>]. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_a6b8ead2-060c-4525-ae16-dbf6f38c2ddb"></a>   <a name="section-4.4"></a>    <p></p>    <h2>4.4 Nursing Mothers</h2>    <p class="First">Fluvastatin is secreted into the breast milk of animals and because HMG-CoA reductase inhibitors have the potential to cause serious adverse reactions in nursing infants, women who require treatment with fluvastatin capsules should be advised not to breastfeed their infants [<span class="Italics">see Use in Specific Populations (<a href="#i4i_nursing_mothers_id_da971182-d2fc-4775-b59f-98d27dd54a66">8.3</a>)</span>]. </p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">5 WARNINGS AND PRECAUTIONS</a> <div class="Section toggle-content closed" data-sectioncode="43685-7">   <a name="i4i_warnings_precautions_id_68dbc097-fd93-41c3-8ab6-ce0869667427"></a>  <a name="section-5"></a>   <p></p>    <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_e04b0745-ab1b-4bfc-b72e-ea8713c0a247"></a>   <a name="section-5.1"></a>    <p></p>    <h2>5.1 Skeletal Muscle</h2>    <p class="First"> <span class="Bold">Rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with fluvastatin capsules and other drugs in this class. </span> </p>    <p>Fluvastatin capsules should be prescribed with caution in patients with predisposing factors for myopathy. These factors include advanced age (&gt; 65 years), renal impairment, and inadequately treated hypothyroidism. </p>    <p>The risk of myopathy and/or rhabdomyolysis with statins is increased with concurrent therapy with cyclosporine, erythromycin, fibrates or niacin. Myopathy was not observed in a clinical trial in 74 patients involving patients who were treated with fluvastatin sodium together with niacin. Isolated cases of myopathy have been reported during postmarketing experience with concomitant administration of fluvastatin sodium and colchicine. No information is available on the pharmacokinetic interaction between fluvastatin sodium and colchicine.</p>    <p>Uncomplicated myalgia has also been reported in fluvastatin sodium-treated patients [<span class="Italics">see Adverse Reactions (<a href="#i4i_adverse_effects_id_15245b83-9864-428f-8a5d-8be0dbebd828">6</a>)</span>]. In clinical trials, uncomplicated myalgia has been observed infrequently in patients treated with fluvastatin sodium at rates indistinguishable from placebo. Myopathy, defined as muscle aching or muscle weakness in conjunction with increases in CPK values to greater than 10 times the upper limit of normal, was &lt; 0.1% in fluvastatin clinical trials. Myopathy should be considered in any patient with diffuse myalgias, muscle tenderness or weakness, and/or marked elevation of CPK. </p>    <p>There have been rare reports of immune-mediated necrotizing myopathy (IMNM), an autoimmune myopathy, associated with statin use. IMNM is characterized by: proximal muscle weakness and elevated serum creatine kinase, which persist despite discontinuation of statin treatment; muscle biopsy showing necrotizing myopathy without significant inflammation; improvement with immunosuppressive agents. </p>    <p>All patients should be advised to promptly report to their physician unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever or if muscle signs and symptoms persist after discontinuing fluvastatin. </p>    <p>Fluvastatin sodium therapy should be discontinued if markedly elevated CPK levels occur or myopathy is diagnosed or suspected. Fluvastatin sodium therapy should also be temporarily withheld in any patient experiencing an acute or serious condition predisposing to the development of renal failure secondary to rhabdomyolysis, e.g., sepsis; hypotension; major surgery; trauma; severe metabolic, endocrine, or electrolyte disorders; or uncontrolled epilepsy. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_8af78cea-813b-44db-ada4-217115af1f2c"></a>   <a name="section-5.2"></a>    <p></p>    <h2>5.2 Liver Enzymes</h2>    <p class="First">Increases in serum transaminases (aspartate aminotransferase [AST]/serum glutamic-oxaloacetic transaminase, or alanine aminotransferase [ALT]/serum glutamic-pyruvic transaminase) have been reported with HMG-CoA reductase inhibitors, including fluvastatin sodium. In most cases, the elevations were transient and resolved or improved on continued therapy or after a brief interruption in therapy. </p>    <p>Approximately 1.1% of patients treated with fluvastatin capsules in worldwide trials developed dose-related, persistent elevations of serum transaminase levels to more than 3 times the upper limit of normal. Fourteen of these patients (0.6%) were discontinued from therapy. In all clinical trials, a total of 33/2969 patients (1.1%) had persistent transaminase elevations with an average fluvastatin sodium exposure of approximately 71.2 weeks; 19 of these patients (0.6%) were discontinued. The majority of patients with these abnormal biochemical findings were asymptomatic. </p>    <p>In a pooled analysis of all placebo-controlled studies in which fluvastatin capsules were used, persistent transaminase elevations (&gt; 3 times the upper limit of normal [ULN] on two consecutive weekly measurements) occurred in 0.2%, 1.5%, and 2.7% of patients treated with daily doses of 20, 40, and 80 mg (titrated to 40 mg twice daily) fluvastatin capsules, respectively. Ninety-one percent of the cases of persistent liver function test abnormalities (20 of 22 patients) occurred within 12 weeks of therapy and in all patients with persistent liver function test abnormalities there was an abnormal liver function test present at baseline or by Week 8. </p>    <p>In the pooled analysis of the 24 week controlled trials, persistent transaminase elevation occurred in 1.8% and 4.9% of patients treated with fluvastatin capsules, 40 mg and fluvastatin capsules, 40 mg twice daily, respectively. </p>    <p>It is recommended that liver enzyme tests be performed prior to the initiation of fluvastatin sodium, and if signs or symptoms of liver injury occur. </p>    <p>There have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins, including fluvastatin. If serious liver injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatment with fluvastatin sodium, promptly interrupt therapy. If an alternate etiology is not found do not restart fluvastatin sodium. </p>    <p>In very rare cases, possibly drug-related hepatitis was observed that resolved upon discontinuation of treatment.<span class="Sup">1 </span>Active liver disease or unexplained serum transaminase elevations are contraindications to the use of fluvastatin sodium [<span class="Italics">see Contraindications (<a href="#i4i_contraindications_id_386b27c8-1942-472b-a659-de72694c59b7">4</a>) and Warnings and Precautions (<a href="#i4i_section_id_8af78cea-813b-44db-ada4-217115af1f2c">5.2</a>)</span>]. Caution should be exercised when fluvastatin sodium is administered to patients with a history of liver disease or heavy alcohol ingestion [<span class="Italics">see Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_a7b9b990-5623-40e8-aae9-f0d439cc5373">12.3</a>)</span>]. Such patients should be closely monitored. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_296b8c3c-de21-40d3-b2ce-cc9411d6b65f"></a>   <a name="section-5.3"></a>    <p></p>    <h2>5.3 Endocrine Effects</h2>    <p class="First">Increases in HbA1c and fasting serum glucose levels have been reported with HMG-CoA reductase inhibitors, including fluvastatin sodium.</p>    <p>Statins interfere with cholesterol synthesis and lower circulating cholesterol levels and, as such, might theoretically blunt adrenal or gonadal steroid hormone production. </p>    <p>Fluvastatin sodium exhibited no effect upon non-stimulated cortisol levels and demonstrated no effect upon thyroid metabolism as assessed by measurement of thyroid stimulating hormone (TSH). Small declines in total serum testosterone have been noted in treated groups, but no commensurate elevation in LH occurred, suggesting that the observation was not due to a direct effect upon testosterone production. No effect upon FSH in males was noted. Due to the limited number of premenopausal females studied to date, no conclusions regarding the effect of fluvastatin sodium upon female sex hormones may be made. </p>    <p>Two clinical studies in patients receiving fluvastatin at doses up to 80 mg daily for periods of 24 to 28 weeks demonstrated no effect of treatment upon the adrenal response to ACTH stimulation. A clinical study evaluated the effect of fluvastatin at doses up to 80 mg daily for 28 weeks upon the gonadal response to HCG stimulation. Although the mean total testosterone response was significantly reduced (p &lt; 0.05) relative to baseline in the 80 mg group, it was not significant in comparison to the changes noted in groups receiving either 40 mg of fluvastatin or placebo. </p>    <p>Patients treated with fluvastatin sodium who develop clinical evidence of endocrine dysfunction should be evaluated appropriately. Caution should be exercised if a statin or other agent used to lower cholesterol levels is administered to patients receiving other drugs (e.g., ketoconazole, spironolactone, cimetidine) that may decrease the levels of endogenous steroid hormones. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_7832c0e7-e00f-4710-a47e-caeb5a7471ec"></a>   <a name="section-5.4"></a>    <p></p>    <h2>5.4 CNS Toxicity</h2>    <p class="First">CNS effects, as evidenced by decreased activity, ataxia, loss of righting reflex, and ptosis were seen in the following animal studies: the 18 month mouse carcinogenicity study at 50 mg/kg/day, the 6 month dog study at 36 mg/kg/day, the 6 month hamster study at 40 mg/kg/day, and in acute, high-dose studies in rats and hamsters (50 mg/kg), rabbits (300 mg/kg) and mice (1500 mg/kg). CNS toxicity in the acute high-dose studies was characterized (in mice) by conspicuous vacuolation in the ventral white columns of the spinal cord at a dose of 5000 mg/kg and (in rats) by edema with separation of myelinated fibers of the ventral spinal tracts and sciatic nerve at a dose of 1500 mg/kg. CNS toxicity, characterized by periaxonal vacuolation, was observed in the medulla of dogs that died after treatment for 5 weeks with 48 mg/kg/day; this finding was not observed in the remaining dogs when the dose level was lowered to 36 mg/kg/day. CNS vascular lesions, characterized by perivascular hemorrhages, edema, and mononuclear cell infiltration of perivascular spaces, have been observed in dogs treated with other members of this drug class. No CNS lesions have been observed after chronic treatment for up to 2 years with fluvastatin in the mouse (at doses up to 350 mg/kg/day), rat (up to 24 mg/kg/day), or dog (up to 16 mg/kg/day). </p>    <p>Prominent bilateral posterior Y suture lines in the ocular lens were seen in dogs after treatment with 1, 8, and 16 mg/kg/day for 2 years. </p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">6 ADVERSE REACTIONS</a> <div class="Section toggle-content closed" data-sectioncode="34084-4">   <a name="i4i_adverse_effects_id_15245b83-9864-428f-8a5d-8be0dbebd828"></a>  <a name="section-6"></a>   <p></p>    <p class="First">The following serious adverse reactions are discussed in greater detail in other sections of the label: </p>   <ul>    <li>Rhabdomyolysis with myoglobinuria and acute renal failure and myopathy (including myositis) [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_e04b0745-ab1b-4bfc-b72e-ea8713c0a247">5.1</a>)</span>]. </li>    <li>Liver Enzyme Abnormalities [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_8af78cea-813b-44db-ada4-217115af1f2c">5.2</a>)</span>]. </li>   </ul>   <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_8f14ec0d-1282-4d95-acbb-2f9e4f64dae2"></a>   <a name="section-6.1"></a>    <p></p>    <h2>6.1 Clinical Studies Experience in Adult Patients</h2>    <p class="First">Because clinical studies on fluvastatin capsules are conducted in varying study populations and study designs, the frequency of adverse reactions observed in the clinical studies of fluvastatin capsules cannot be directly compared with that in the clinical studies of other statins and may not reflect the frequency of adverse reactions observed in clinical practice. </p>    <p>In the fluvastatin capsules placebo-controlled clinical trials database of 2326 patients treated with fluvastatin capsules<span class="Sup">1 </span> (age range 18 to 75 years, 44% women, 94% Caucasians, 4% Blacks, 2% other ethnicities) with a median treatment duration of 24 weeks, 3.4% of patients on fluvastatin capsules and 2.3% patients on placebo discontinued due to adverse reactions regardless of causality. The most common adverse reactions that led to treatment discontinuation and occurred at an incidence greater than placebo were: transaminase increased (0.8%), upper abdominal pain (0.3%), dyspepsia (0.3%), fatigue (0.2%) and diarrhea (0.2%). </p>    <p>Clinically relevant adverse experiences occurring in the fluvastatin capsules controlled studies with a frequency  2%, regardless of causality, included the following: </p>    <a name="id_9fc4e5a5-3646-4e1d-bfa2-57d944254d4f"></a>    <div class="scrollingtable">    <table border="single" width="365">      <caption>       <span>Table 1: Clinical Adverse Events Reported in &gt; 2% in Patients Treated With Fluvastatin Capsules and at an Incidence Greater Than Placebo in Placebo-Controlled Trials Regardless of Causality (% of Patients) Pooled Dosages</span>      </caption>      <colgroup>      <col width="24.5%" />       <col width="36.1%" />       <col width="19.7%" />       <col width="19.7%" />      </colgroup>     <tfoot>       <tr>        <td align="left" colspan="4">         <dl class="Footnote">          <dt>           <a href="#footnote-reference-1" name="footnote-1">*</a>          </dt>          <dd>          Controlled trials with fluvastatin capsules (20 and 40 mg daily and 40 mg twice daily) compared to placebo          </dd>         </dl> </td>       </tr>      </tfoot>      <tbody class="Headless">       <tr class="First">        <td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>       <td class="Botrule Rrule" align="left" valign="top"></td>       <td class="Botrule Rrule" align="center" valign="top"> <p class="First">Fluvastatin Capsules<a class="Sup" href="#footnote-1" name="footnote-reference-1">*</a> </p> <p>N = 2326</p>(%)</td>       <td class="Botrule Rrule" align="center" valign="top"> <p class="First">Placebo<a class="Sup" href="#footnote-1">*</a> </p> <p>N = 960</p>(%)</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="left" valign="top">Musculoskeletal</td>       <td class="Botrule Rrule" align="left" valign="top">Myalgia</td>       <td class="Botrule Rrule" align="center" valign="top">5.0</td>       <td class="Botrule Rrule" align="center" valign="top">4.5</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="left" valign="top"></td>       <td class="Botrule Rrule" align="left" valign="top">Arthritis</td>       <td class="Botrule Rrule" align="center" valign="top">2.1</td>       <td class="Botrule Rrule" align="center" valign="top">2.0</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="left" valign="top"></td>       <td class="Botrule Rrule" align="left" valign="top">Arthropathy</td>       <td class="Botrule Rrule" align="center" valign="top">NA</td>       <td class="Botrule Rrule" align="center" valign="top">NA</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="left" valign="top">Respiratory</td>       <td class="Botrule Rrule" align="left" valign="top">Sinusitis</td>       <td class="Botrule Rrule" align="center" valign="top">2.6</td>       <td class="Botrule Rrule" align="center" valign="top">1.9</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="left" valign="top"></td>       <td class="Botrule Rrule" align="left" valign="top">Bronchitis</td>       <td class="Botrule Rrule" align="center" valign="top">1.8</td>       <td class="Botrule Rrule" align="center" valign="top">1.0</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="left" valign="top">Gastrointestinal</td>       <td class="Botrule Rrule" align="left" valign="top">Dyspepsia</td>       <td class="Botrule Rrule" align="center" valign="top">7.9</td>       <td class="Botrule Rrule" align="center" valign="top">3.2</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="left" valign="top"></td>       <td class="Botrule Rrule" align="left" valign="top">Diarrhea</td>       <td class="Botrule Rrule" align="center" valign="top">4.9</td>       <td class="Botrule Rrule" align="center" valign="top">4.2</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="left" valign="top"></td>       <td class="Botrule Rrule" align="left" valign="top">Abdominal pain</td>       <td class="Botrule Rrule" align="center" valign="top">4.9</td>       <td class="Botrule Rrule" align="center" valign="top">3.8</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="left" valign="top"></td>       <td class="Botrule Rrule" align="left" valign="top">Nausea</td>       <td class="Botrule Rrule" align="center" valign="top">3.2</td>       <td class="Botrule Rrule" align="center" valign="top">2.0</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="left" valign="top"></td>       <td class="Botrule Rrule" align="left" valign="top">Flatulence</td>       <td class="Botrule Rrule" align="center" valign="top">2.6</td>       <td class="Botrule Rrule" align="center" valign="top">2.5</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="left" valign="top"></td>       <td class="Botrule Rrule" align="left" valign="top">Tooth disorder</td>       <td class="Botrule Rrule" align="center" valign="top">2.1</td>       <td class="Botrule Rrule" align="center" valign="top">1.7</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="left" valign="top">Psychiatric</td>       <td class="Botrule Rrule" align="left" valign="top">Insomnia</td>       <td class="Botrule Rrule" align="center" valign="top">2.7</td>       <td class="Botrule Rrule" align="center" valign="top">1.4</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="left" valign="top">Genitourinary</td>       <td class="Botrule Rrule" align="left" valign="top">Urinary tract infection</td>       <td class="Botrule Rrule" align="center" valign="top">1.6</td>       <td class="Botrule Rrule" align="center" valign="top">1.1</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="left" valign="top">Miscellaneous</td>       <td class="Botrule Rrule" align="left" valign="top">Headache</td>       <td class="Botrule Rrule" align="center" valign="top">8.9</td>       <td class="Botrule Rrule" align="center" valign="top">7.8</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="left" valign="top"></td>       <td class="Botrule Rrule" align="left" valign="top">Influenza-like symptoms</td>       <td class="Botrule Rrule" align="center" valign="top">5.1</td>       <td class="Botrule Rrule" align="center" valign="top">5.7</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="left" valign="top"></td>       <td class="Botrule Rrule" align="left" valign="top">Accidental Trauma</td>       <td class="Botrule Rrule" align="center" valign="top">5.1</td>       <td class="Botrule Rrule" align="center" valign="top">4.8</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="left" valign="top"></td>       <td class="Botrule Rrule" align="left" valign="top">Fatigue</td>       <td class="Botrule Rrule" align="center" valign="top">2.7</td>       <td class="Botrule Rrule" align="center" valign="top">2.3</td>       </tr>       <tr class="Last">        <td class="Botrule Lrule Rrule" align="left" valign="top"></td>       <td class="Rrule" align="left" valign="top">Allergy</td>       <td class="Rrule" align="center" valign="top">2.3</td>       <td class="Botrule Rrule" align="center" valign="top">2.2</td>       </tr>      </tbody>     </table>   </div>    <p> <span class="Italics">Fluvastatin Capsules Intervention Prevention Study</span> </p>    <p>In the Fluvastatin Capsules Intervention Prevention Study, the effect of fluvastatin capsules, 40 mg, administered twice daily on the risk of recurrent cardiac events was assessed in 1677 patients with CHD who had undergone a percutaneous coronary intervention (PCI) procedure. This was a multicenter, randomized, double-blind, placebo-controlled study, patients were treated with dietary/lifestyle counseling and either fluvastatin capsules, 40 mg (n = 844) or placebo (n = 833) given twice daily for a median of 3.9 years [<span class="Italics">see Clinical Studies (<a href="#i4i_section_id_f11bada3-f904-4a49-b5db-5276fee36772">14.3</a>)</span>]. </p>    <a name="id_06ed5234-b47a-4fdf-bd26-f249da17afe0"></a>    <div class="scrollingtable">    <table border="single" width="443">      <caption>       <span>Table 2: Clinical Adverse Events Reported in  2% in Patients Treated With Fluvastatin Sodium and at an Incidence Greater Than Placebo in the Trial Regardless of Causality (% of Patients) </span>      </caption>      <colgroup>      <col width="31.7%" />       <col width="30.5%" />       <col width="20.3%" />       <col width="17.5%" />      </colgroup>     <tbody class="Headless">       <tr class="First">        <td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>       <td class="Botrule Rrule" align="left" valign="top"></td>       <td class="Botrule Rrule" align="left" valign="top"> <p class="First">Fluvastatin Capsules, </p> <p>40 mg b.i.d.</p> <p>N = 822</p>(%)</td>       <td class="Botrule Rrule" align="left" valign="top"> <p class="First">Placebo</p> <p>N = 818</p>(%)</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="left" valign="top">Cardiac disorders</td>       <td class="Botrule Rrule" align="left" valign="top">Atrial fibrillation</td>       <td class="Botrule Rrule" align="left" valign="top">2.4</td>       <td class="Botrule Rrule" align="left" valign="top">2.0</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="left" valign="top">Gastrointestinal disorders</td>       <td class="Botrule Rrule" align="left" valign="top">Abdominal pain upper</td>       <td class="Botrule Rrule" align="left" valign="top">6.3</td>       <td class="Botrule Rrule" align="left" valign="top">4.5</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="left" valign="top"></td>       <td class="Botrule Rrule" align="left" valign="top">Constipation</td>       <td class="Botrule Rrule" align="left" valign="top">3.3</td>       <td class="Botrule Rrule" align="left" valign="top">2.1</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="left" valign="top"></td>       <td class="Botrule Rrule" align="left" valign="top">Dyspepsia</td>       <td class="Botrule Rrule" align="left" valign="top">4.5</td>       <td class="Botrule Rrule" align="left" valign="top">4.0</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="left" valign="top"></td>       <td class="Botrule Rrule" align="left" valign="top">Gastric disorder</td>       <td class="Botrule Rrule" align="left" valign="top">2.7</td>       <td class="Botrule Rrule" align="left" valign="top">2.1</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="left" valign="top"></td>       <td class="Botrule Rrule" align="left" valign="top">Nausea</td>       <td class="Botrule Rrule" align="left" valign="top">2.7</td>       <td class="Botrule Rrule" align="left" valign="top">2.3</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="left" valign="top">General disorders</td>       <td class="Botrule Rrule" align="left" valign="top">Fatigue</td>       <td class="Botrule Rrule" align="left" valign="top">4.7</td>       <td class="Botrule Rrule" align="left" valign="top">3.8</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="left" valign="top"></td>       <td class="Botrule Rrule" align="left" valign="top">Edema peripheral</td>       <td class="Botrule Rrule" align="left" valign="top">4.4</td>       <td class="Botrule Rrule" align="left" valign="top">2.9</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="left" valign="top">Infections and infestations</td>       <td class="Botrule Rrule" align="left" valign="top">Bronchitis</td>       <td class="Botrule Rrule" align="left" valign="top">2.3</td>       <td class="Botrule Rrule" align="left" valign="top">2.0</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="left" valign="top"></td>       <td class="Botrule Rrule" align="left" valign="top">Nasopharyngitis</td>       <td class="Botrule Rrule" align="left" valign="top">2.8</td>       <td class="Botrule Rrule" align="left" valign="top">2.1</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="left" valign="top">Musculoskeletal and connective tissue disorders</td>       <td class="Botrule Rrule" align="left" valign="top">Arthralgia</td>       <td class="Botrule Rrule" align="left" valign="top">2.1</td>       <td class="Botrule Rrule" align="left" valign="top">1.8</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="left" valign="top"></td>       <td class="Botrule Rrule" align="left" valign="top">Myalgia</td>       <td class="Botrule Rrule" align="left" valign="top">2.2</td>       <td class="Botrule Rrule" align="left" valign="top">1.6</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="left" valign="top"></td>       <td class="Botrule Rrule" align="left" valign="top">Pain in extremity</td>       <td class="Botrule Rrule" align="left" valign="top">4.1</td>       <td class="Botrule Rrule" align="left" valign="top">2.7</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="left" valign="top">Nervous system disorders</td>       <td class="Botrule Rrule" align="left" valign="top">Dizziness</td>       <td class="Botrule Rrule" align="left" valign="top">3.9</td>       <td class="Botrule Rrule" align="left" valign="top">3.5</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="left" valign="top"></td>       <td class="Botrule Rrule" align="left" valign="top">Syncope</td>       <td class="Botrule Rrule" align="left" valign="top">2.4</td>       <td class="Botrule Rrule" align="left" valign="top">2.2</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="left" valign="top">Respiratory disorders</td>       <td class="Botrule Rrule" align="left" valign="top">Dyspnea exertional</td>       <td class="Botrule Rrule" align="left" valign="top">2.8</td>       <td class="Botrule Rrule" align="left" valign="top">2.4</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="left" valign="top">Vascular disorders</td>       <td class="Botrule Rrule" align="left" valign="top">Hypertension</td>       <td class="Botrule Rrule" align="left" valign="top">5.8</td>       <td class="Botrule Rrule" align="left" valign="top">4.2</td>       </tr>       <tr class="Last">        <td class="Botrule Lrule Rrule" align="left" valign="top"></td>       <td class="Rrule" align="left" valign="top">Intermittent claudication</td>       <td class="Rrule" align="left" valign="top">2.3</td>       <td class="Botrule Rrule" align="left" valign="top">2.1</td>       </tr>      </tbody>     </table>   </div>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_c02f9837-5a79-42eb-b820-d82be2a0842f"></a>   <a name="section-6.2"></a>    <p></p>    <h2>6.2 Clinical Studies Experience in Pediatric Patients</h2>    <p class="First">In patients aged &lt; 18 years, efficacy and safety have not been studied for treatment periods longer than two years. </p>    <p>In two open-label, uncontrolled studies, 66 boys and 48 girls with heterozygous familial hypercholesterolemia (9 to 16 years of age, 80% Caucasian, 19% Other [mixed ethnicity], 1% Asians) were treated with fluvastatin sodium administered as fluvastatin capsules, 20 mg to 40 mg twice daily, or fluvastatin sodium extended-release tablets, 80 mg [<span class="Italics">see Clinical Studies (<a href="#i4i_section_id_e9d04278-739f-4353-bf70-63bcb840b447">14.2</a>) and Use in Specific Populations (<a href="#i4i_pediatric_use_id_04dfda7c-6798-4c02-be26-10b73863880f">8.4</a>)</span>]. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_3334cfea-8720-4c13-950c-fa7161146527"></a>   <a name="section-6.3"></a>    <p></p>    <h2>6.3 Postmarketing Experience</h2>    <p class="First">Because adverse reactions from spontaneous reports are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following effects have been reported with drugs in this class. Not all the effects listed below have necessarily been associated with fluvastatin sodium therapy. </p>    <p> <span class="Bold"><span class="Italics">Musculoskeletal: </span></span>muscle cramps, myalgia, myopathy, rhabdomyolysis, arthralgias, muscle spasms, muscle weakness, myositis. </p>    <p>There have been rare reports of immune-mediated necrotizing myopathy associated with statin use [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_e04b0745-ab1b-4bfc-b72e-ea8713c0a247">5.1</a>)</span>]. </p>    <p> <span class="Bold"><span class="Italics">Neurological: </span></span>dysfunction of certain cranial nerves (including alteration of taste, impairment of extra-ocular movement, facial paresis), tremor, dizziness, vertigo, paresthesia, hypoesthesia, dysesthesia, peripheral neuropathy, peripheral nerve palsy. </p>    <p>There have been rare postmarketing reports of cognitive impairment (e.g., memory loss, forgetfulness, amnesia, memory impairment, confusion) associated with statin use. These cognitive issues have been reported for all statins. The reports are generally nonserious, and reversible upon statin discontinuation, with variable times to symptom onset (1 day to years) and symptom resolution (median of 3 weeks). </p>    <p> <span class="Bold"><span class="Italics">Psychiatric: </span></span>anxiety, insomnia, depression, psychic disturbances </p>    <p> <span class="Bold"><span class="Italics">Hypersensitivity Reactions: </span></span>An apparent hypersensitivity syndrome has been reported rarely which has included one or more of the following features: anaphylaxis, angioedema, lupus erythematosus-like syndrome, polymyalgia rheumatica, vasculitis, purpura, thrombocytopenia, leukopenia, hemolytic anemia, positive ANA, ESR (erythrocyte sedimentation rate) increase, eosinophilia, arthritis, arthralgia, urticaria, asthenia, photosensitivity reaction, fever, chills, flushing, malaise, dyspnea, toxic epidermal necrolysis, erythema multiforme, including Stevens-Johnson syndrome. </p>    <p> <span class="Bold"><span class="Italics">Gastrointestinal: </span></span>pancreatitis, hepatitis, including chronic active hepatitis, cholestatic jaundice, fatty change in liver, cirrhosis, fulminant hepatic necrosis, hepatoma, anorexia, vomiting, fatal and non-fatal hepatic failure. </p>    <p> <span class="Bold"><span class="Italics">Skin: </span></span>rash, dermatitis, including bullous dermatitis, eczema, alopecia, pruritus, a variety of skin changes (e.g., nodules, discoloration, dryness of skin/mucous membranes, changes to hair/nails). </p>    <p> <span class="Bold"><span class="Italics">Reproductive: </span></span>gynecomastia, loss of libido, erectile dysfunction. </p>    <p> <span class="Bold"><span class="Italics">Eye: </span></span>progression of cataracts (lens opacities), ophthalmoplegia. </p>    <p> <span class="Bold"><span class="Italics">Laboratory abnormalities: </span></span>elevated transaminases, alkaline phosphatase, gamma-glutamyl transpeptidase and bilirubin; thyroid function abnormalities. </p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">7 DRUG INTERACTIONS</a> <div class="Section toggle-content closed" data-sectioncode="34073-7">   <a name="i4i_interactions_id_25d02351-69fd-4e29-9276-8e0b77bc6752"></a>  <a name="section-7"></a>   <p></p>    <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_1cd8ed8a-19fc-4b25-afa1-d811fff09609"></a>   <a name="section-7.1"></a>    <p></p>    <h2>7.1 Cyclosporine</h2>    <p class="First">Cyclosporine coadministration increases fluvastatin exposure. Therefore, in patients taking cyclosporine, therapy should be limited to fluvastatin 20 mg twice daily [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_e04b0745-ab1b-4bfc-b72e-ea8713c0a247">5.1</a>) and Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_a7b9b990-5623-40e8-aae9-f0d439cc5373">12.3</a>)</span>].</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_7f42ffc0-b116-4c0d-8b97-2214c2a32d99"></a>   <a name="section-7.2"></a>    <p></p>    <h2>7.2 Fluconazole</h2>    <p class="First">Administration of fluvastatin 40 mg single dose to healthy volunteers pre-treated with fluconazole for 4 days results in an increase of fluvastatin exposure. Therefore, in patients taking fluconazole, therapy should be limited to fluvastatin 20 mg twice daily [<span class="Italics">see Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_a7b9b990-5623-40e8-aae9-f0d439cc5373">12.3</a>)</span>]<span class="Italics">. </span> </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_403d9621-1c84-4537-8964-cb87ef3d0b52"></a>   <a name="section-7.3"></a>    <p></p>    <h2>7.3 Gemfibrozil</h2>    <p class="First">Due to an increased risk of myopathy/rhabdomyolysis when HMG-CoA reductase inhibitors are coadministered with gemfibrozil, concomitant administration of fluvastatin sodium with gemfibrozil should be avoided.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_ada36022-3fd3-4ac0-9d35-1ece37c1e828"></a>   <a name="section-7.4"></a>    <p></p>    <h2>7.4 Other Fibrates</h2>    <p class="First">Because it is known that the risk of myopathy during treatment with HMG-CoA reductase inhibitors is increased with concurrent administration of other fibrates, fluvastatin sodium should be administered with caution when used concomitantly with other fibrates [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_e04b0745-ab1b-4bfc-b72e-ea8713c0a247">5.1</a>) and Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_a7b9b990-5623-40e8-aae9-f0d439cc5373">12.3</a>)</span>]. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_b8b8fb97-7867-46b7-a9dc-fe7cf8c4cb5c"></a>   <a name="section-7.5"></a>    <p></p>    <h2>7.5 Niacin</h2>    <p class="First">The risk of skeletal muscle effects may be enhanced when fluvastatin sodium is used in combination with lipid-modifying doses ( 1 g/day) of niacin; a reduction in fluvastatin sodium dosage should be considered in this setting [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_e04b0745-ab1b-4bfc-b72e-ea8713c0a247">5.1</a>)</span>].</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_d87285fd-1c46-419c-ae78-c9306ecdb9a5"></a>   <a name="section-7.6"></a>    <p></p>    <h2>7.6 Glyburide</h2>    <p class="First">Concomitant administration of fluvastatin and glyburide increased glyburide exposures. Patients on concomitant therapy of glyburide and fluvastatin should continue to be monitored appropriately [<span class="Italics">see Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_a7b9b990-5623-40e8-aae9-f0d439cc5373">12.3</a>)</span>]. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_0a1e598c-0006-4b8f-aef7-793c865af28b"></a>   <a name="section-7.7"></a>    <p></p>    <h2>7.7 Phenytoin</h2>    <p class="First">Concomitant administration of fluvastatin and phenytoin increased phenytoin exposures. Patients should continue to be monitored appropriately when fluvastatin therapy is initiated or when fluvastatin dose is changed [<span class="Italics">see Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_a7b9b990-5623-40e8-aae9-f0d439cc5373">12.3</a>)</span>]. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_aac62781-53f2-45a1-8f58-df78e0a33e71"></a>   <a name="section-7.8"></a>    <p></p>    <h2>7.8 Warfarin</h2>    <p class="First">Bleeding and/or increased prothrombin times have been reported in patients taking coumarin anticoagulants concomitantly with other HMG-CoA reductase inhibitors. Therefore, patients receiving warfarin-type anticoagulants should have their prothrombin times closely monitored when fluvastatin sodium is initiated or the dosage of fluvastatin sodium is changed. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_0525850a-4d50-49cc-8099-527e83b2a133"></a>   <a name="section-7.9"></a>    <p></p>    <h2>7.9 Colchicine </h2>    <p class="First">Cases of myopathy, including rhabdomyolysis, have been reported with fluvastatin coadministered with colchicine, and caution should be exercised when prescribing fluvastatin with colchicine.</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">8 USE IN SPECIFIC POPULATIONS</a> <div class="Section toggle-content closed" data-sectioncode="43684-0">   <a name="i4i_specific_populations_id_9378f679-e3dc-4eab-a3ab-69799517adfe"></a>  <a name="section-8"></a>   <p></p>    <div class="Section" data-sectioncode="42228-7">    <a name="i4i_pregnancy_id_f55b8c53-f167-4135-8643-9a208663e558"></a>   <a name="section-8.1"></a>    <p></p>    <h2>8.1 Pregnancy</h2>    <div class="Section" data-sectioncode="34077-8">     <a name="i4i_teratogenic_id_406845aa-c718-441f-895e-54ba7299286d"></a>    <a name="section-8.1.1"></a>     <p></p>     <h3>Teratogenic Effects</h3>     <div class="Section" data-sectioncode="42229-5">      <a name="i4i_pregnancy_X_id_56088fd3-670b-4175-8361-072539ea339a"></a>     <a name="section-8.1.1.1"></a>      <p></p>      <h4>Pregnancy category X</h4>      <p class="First">Fluvastatin sodium is contraindicated in women who are or may become pregnant [<span class="Italics">see Contraindications (<a href="#i4i_contraindications_id_386b27c8-1942-472b-a659-de72694c59b7">4</a>)</span>]. </p>      <p>Lipid lowering drugs are contraindicated during pregnancy, because cholesterol and cholesterol derivatives are needed for normal fetal development. Serum cholesterol and triglycerides increase during normal pregnancy. Atherosclerosis is a chronic process, and discontinuation of lipid-lowering drugs during pregnancy should have little impact on long-term outcomes of primary hypercholesterolemia therapy. </p>      <p>There are no adequate and well-controlled studies of use with fluvastatin sodium during pregnancy. Rare reports of congenital anomalies have been received following intrauterine exposure to other statins. In a review<span class="Sup">2 </span>of about 100 prospectively followed pregnancies in women exposed to other statins, the incidences of congenital anomalies, spontaneous abortions, and fetal deaths/stillbirths did not exceed the rate expected in the general population. The number of cases is adequate only to exclude a 3 to 4 fold increase in congenital anomalies over background incidence. In 89% of prospectively followed pregnancies, drug treatment was initiated prior to pregnancy and was discontinued at some point in the first trimester when pregnancy was identified. </p>      <p>Teratology studies with fluvastatin in rats and rabbits showed maternal toxicity at high dose levels, but there was no evidence of embryotoxic or teratogenic potential [<span class="Italics">see Nonclinical Toxicology (<a href="#i4i_nonclinical_toxicology_id_13cd65f0-5db7-4669-a1bd-009e40fef828">13</a>)</span>]. </p>      <p>Fluvastatin sodium should be administered to women of child-bearing potential only when such patients are highly unlikely to conceive and have been informed of the potential hazards. If a woman becomes pregnant while taking fluvastatin sodium, the drug should be discontinued and the patient advised again as to the potential hazards to the fetus. </p>     </div>    </div>   </div>   <div class="Section" data-sectioncode="34080-2">    <a name="i4i_nursing_mothers_id_da971182-d2fc-4775-b59f-98d27dd54a66"></a>   <a name="section-8.2"></a>    <p></p>    <h2>8.3 Nursing Mothers</h2>    <p class="First">Based on animal data, fluvastatin is present in breast milk in a 2:1 ratio (milk:plasma). Because of the potential for serious adverse reactions in nursing infants, nursing women should not take fluvastatin sodium [<span class="Italics">see Contraindications (<a href="#i4i_contraindications_id_386b27c8-1942-472b-a659-de72694c59b7">4</a>)</span>]. </p>   </div>   <div class="Section" data-sectioncode="34081-0">    <a name="i4i_pediatric_use_id_04dfda7c-6798-4c02-be26-10b73863880f"></a>   <a name="section-8.3"></a>    <p></p>    <h2>8.4 Pediatric Use</h2>    <p class="First">The safety and efficacy of fluvastatin sodium in children and adolescent patients 9 to 16 years of age with heterozygous familial hypercholesterolemia have been evaluated in open-label, uncontrolled clinical trials for a duration of two years. The most common adverse events observed were influenza and infections. In these limited uncontrolled studies, there was no detectable effect on growth or sexual maturation in the adolescent boys or on menstrual cycle length in girls [<span class="Italics">see Clinical Studies (<a href="#i4i_section_id_e9d04278-739f-4353-bf70-63bcb840b447">14.2</a>), Adverse Reactions (<a href="#i4i_section_id_3334cfea-8720-4c13-950c-fa7161146527">6.3</a>), and Dosage and Administration (<a href="#i4i_section_id_b8e3f439-b516-4846-a98d-167d87e040b2">2.2</a>)</span>]. Adolescent females should be counseled on appropriate contraceptive methods while on fluvastatin sodium therapy [<span class="Italics">see Contraindications (<a href="#i4i_contraindications_id_386b27c8-1942-472b-a659-de72694c59b7">4</a>)</span>]. </p>   </div>   <div class="Section" data-sectioncode="34082-8">    <a name="i4i_geriatric_use_id_9ad69df3-88a4-4138-ab65-f2e0e58c8eed"></a>   <a name="section-8.4"></a>    <p></p>    <h2>8.5 Geriatric Use</h2>    <p class="First">Fluvastatin exposures were not significantly different between the nonelderly and elderly populations (age  65 years) [<span class="Italics">see Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_a7b9b990-5623-40e8-aae9-f0d439cc5373">12.3</a>)</span>]. Since advanced age ( 65 years) is a predisposing factor for myopathy, fluvastatin sodium should be prescribed with caution in the elderly. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_50ed2b3f-57b5-49a3-a770-a12584db88cd"></a>   <a name="section-8.5"></a>    <p></p>    <h2>8.6 Hepatic Impairment</h2>    <p class="First">Fluvastatin sodium is contraindicated in patients with active liver disease or unexplained, persistent elevations in serum transaminases [<span class="Italics">see Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_a7b9b990-5623-40e8-aae9-f0d439cc5373">12.3</a>)</span>]. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_4dbf5df9-7f17-4a26-b1fc-e95acef063d3"></a>   <a name="section-8.6"></a>    <p></p>    <h2>8.7 Renal Impairment</h2>    <p class="First">Dose adjustments for mild to moderate renal impairment are not necessary. Fluvastatin has not been studied at doses greater than 40 mg in patients with severe renal impairment; therefore caution should be exercised when treating such patients at higher doses [<span class="Italics">see Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_a7b9b990-5623-40e8-aae9-f0d439cc5373">12.3</a>)</span>]. </p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">10 OVERDOSAGE</a> <div class="Section toggle-content closed" data-sectioncode="34088-5">   <a name="i4i_overdosage_id_2aff8315-a179-4300-8f34-751fb58e13e5"></a>  <a name="section-9"></a>   <p></p>    <p class="First">To date, there has been limited experience with overdosage of fluvastatin. If an overdose occurs, it should be treated symptomatically with laboratory monitoring and supportive measures should be instituted as required. The dialyzability of fluvastatin sodium and of its metabolites in humans is not known at present [<span class="Italics">see</span><span class="Italics">Warnings and Precautions (<a href="#i4i_warnings_precautions_id_68dbc097-fd93-41c3-8ab6-ce0869667427">5</a>)</span>]. </p>   <p>In the pediatric population, there have been reports of overdosage with fluvastatin sodium in children including a 2-year-old and the other 3 years of age, either of whom may have possibly ingested fluvastatin sodium. The maximum amount of fluvastatin sodium that could have been ingested was 80 mg (4 x 20 mg capsules). Vomiting was induced by ipecac in both children and no capsules were noted in their emesis. Neither child experienced any adverse symptoms and both recovered from the incident without problems. </p>   <p>In the postmarketing experience there have been reports of accidental ingestion of fluvastatin tablets in infants up to 3 years of age. In one case, increased serum CPK values were noted. There have been reports of intentional overdose in adolescents with the development of hepatic enzyme elevations, convulsions and gastroenteritis/vomiting/diarrhea. </p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">11 DESCRIPTION</a> <div class="Section toggle-content closed" data-sectioncode="34089-3">   <a name="i4i_description_id_5ccc95d8-bf2c-4e3e-bd2c-fb49d5c2eb71"></a>  <a name="section-10"></a>   <p></p>    <p class="First">Fluvastatin sodium is a water-soluble cholesterol lowering agent which acts through the inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. </p>   <p>Fluvastatin sodium is [<span class="Italics">R</span>*,<span class="Italics">S</span>*-(<span class="Italics">E</span>)]-(&plusmn;)-7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1<span class="Italics">H</span>-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid, monosodium salt. Its structural formula is:</p>   <div class="Figure">    <img src="image.cfm?setid=aad8b373-0aec-4efb-8e61-3d8114b31127&name=acd656cf%2D3edc%2D499c%2D9630%2D17ac45753572%2D01%2Ejpg" alt="Structural formula for fluvastatin" />  </div>   <p>C<span class="Sub">24</span>H<span class="Sub">25</span>FNNaO<span class="Sub">4 </span>M.W. 433.46</p>   <p>This molecular entity is the first entirely synthetic HMG-CoA reductase inhibitor, and is in part structurally distinct from the fungal derivatives of this therapeutic class.</p>   <p>Fluvastatin sodium (hydrated form) is a white to pale yellow, brownish-pale yellow, or reddish-pale yellow, hygroscopic powder soluble in water, ethanol, and methanol. Fluvastatin capsules USP contain fluvastatin sodium (hydrated form), equivalent to 20 mg or 40 mg of fluvastatin, for oral administration.</p>   <p> <span class="Italics"><span class="Bold">Active Ingredient:</span></span> fluvastatin sodium (hydrated form) </p>   <p> <span class="Italics"><span class="Bold">Inactive Ingredients:</span></span> black iron oxide, colloidal silicon dioxide, crospovidone, gelatin, lactose monohydrate, magnesium stearate, propylene glycol, red iron oxide, shellac, titanium dioxide, and yellow iron oxide. The imprinting ink may contain potassium hydroxide.</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">12 CLINICAL PHARMACOLOGY</a> <div class="Section toggle-content closed" data-sectioncode="34090-1">   <a name="i4i_clinical_pharmacology_id_711968cd-d5ed-45fa-a383-2fdcce3c2698"></a>  <a name="section-11"></a>   <p></p>    <div class="Section" data-sectioncode="43679-0">    <a name="i4i_mechanism_action_id_24b73423-4b90-492e-9d5b-7186768c8f0e"></a>   <a name="section-11.1"></a>    <p></p>    <h2>12.1 Mechanism of Action</h2>    <p class="First">Fluvastatin sodium is a competitive inhibitor of HMG-CoA reductase, the rate limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) to mevalonate, a precursor of sterols, including cholesterol. The inhibition of cholesterol biosynthesis reduces the cholesterol in hepatic cells, which stimulates the synthesis of LDL receptors and thereby increases the uptake of LDL particles. The end result of these biochemical processes is a reduction of the plasma cholesterol concentration. </p>   </div>   <div class="Section" data-sectioncode="43682-4">    <a name="i4i_pharmacokinetics_id_a7b9b990-5623-40e8-aae9-f0d439cc5373"></a>   <a name="section-11.2"></a>    <p></p>    <h2>12.3 Pharmacokinetics</h2>    <p class="First"> <span class="Bold">Absorption:</span> </p>    <p>Following oral administration of the capsule, fluvastatin reaches peak concentrations in less than 1 hour. The absolute bioavailability is 24% (range 9% to 50%) after administration of a 10 mg dose. </p>    <p>At steady state, administration of fluvastatin with the evening meal results in a 50% decrease in C<span class="Sub">max</span>, an 11% decrease in AUC, and a more than two-fold increase in t<span class="Sub">max</span> as compared to administration 4 hours after the evening meal. No significant differences in the lipid-lowering effects were observed between the two administrations. After single or multiple doses above 20 mg, fluvastatin exhibits saturable first-pass metabolism resulting in more than dose proportional plasma fluvastatin concentrations.</p>    <p>Fluvastatin administered as fluvastatin sodium extended-release 80 mg tablets reaches peak concentration in approximately 3 hours under fasting conditions, after a low fat meal, or 2.5 hours after a low fat meal. The mean relative bioavailability of the extended-release tablet is approximately 29% (range: 9% to 66%) compared to that of the fluvastatin immediate-release capsule administered under fasting conditions. Administration of a high fat meal delayed the absorption (T<span class="Sub">max</span>: 6h) and increased the bioavailability of the extended-release tablet by approximately 50%. However, the maximum concentration of fluvastatin sodium extended-release tablets seen after a high fat meal is less than the peak concentration following a single dose or twice daily dose of the 40 mg fluvastatin capsule. </p>    <p> <span class="Bold">Distribution:</span> </p>    <p>Fluvastatin is 98% bound to plasma proteins. The mean volume of distribution (VD<span class="Sub">ss</span>) is estimated at 0.35 L/kg. At therapeutic concentrations, the protein binding of fluvastatin is not affected by warfarin, salicylic acid and glyburide. </p>    <p> <span class="Bold">Metabolism:</span> </p>    <p>Fluvastatin is metabolized in the liver, primarily via hydroxylation of the indole ring at the 5 and 6 positions. N-dealkylation and beta-oxidation of the side-chain also occurs. The hydroxy metabolites have some pharmacologic activity, but do not circulate in the blood. Fluvastatin has two enantiomers. Both enantiomers of fluvastatin are metabolized in a similar manner. </p>    <p> <span class="Italics">In vitro</span> data indicate that fluvastatin metabolism involves multiple Cytochrome P450 (CYP) isozymes. CYP2C9 isoenzyme is primarily involved in the metabolism of fluvastatin (approximately 75%), while CYP2C8 and CYP3A4 isoenzymes are involved to a much less extent, i.e., approximately 5% and approximately 20%, respectively. </p>    <p> <span class="Bold">Excretion:</span> </p>    <p>Following oral administration, fluvastatin is primarily (about 90%) excreted in the feces as metabolites, with less than 2% present as unchanged drug. Approximately 5% of a radiolabeled oral dose were recovered in urine. The elimination half-life (t<span class="Sub">1/2</span>) of fluvastatin is approximately 3 hours. </p>    <p> <span class="Bold">Specific Populations</span> </p>    <p> <span class="Bold">Renal Impairment:</span> </p>    <p>In patients with moderate to severe renal impairment (CL<span class="Sub">Cr</span> 10 to 40 mL/min), AUC and C<span class="Sub">max</span> increased approximately 1.2 fold after administration of a single dose of 40 mg fluvastatin compared to healthy volunteers. In patients with end-stage renal disease on hemodialysis, the AUC increased by approximately 1.5 fold. Fluvastatin sodium extended-release tablets were not evaluated in patients with renal impairment. However, systemic exposures after administration of fluvastatin sodium extended-release tablets are lower than after the 40 mg immediate-release capsule. </p>    <p> <span class="Bold">Hepatic Impairment:</span> </p>    <p>In patients with hepatic impairment due to liver cirrhosis, fluvastatin AUC and C<span class="Sub">max</span> increased approximately 2.5 fold compared to healthy subjects after administration of a single 40 mg dose. The enantiomer ratios of the two isomers of fluvastatin in hepatic impairment patients were comparable to those observed in healthy subjects. </p>    <p> <span class="Bold">Geriatric:</span> </p>    <p>Plasma levels of fluvastatin are not significantly different in patients age &gt; 65 years compared to patients age 21 to 49 years. </p>    <p> <span class="Bold">Gender:</span> </p>    <p>In a study evaluating the effect of age and gender on fluvastatin pharmacokinetics, there were no significant differences in fluvastatin exposures between males and females, except between younger females and younger males (both ages 21 to 49 years), where there was an approximate 30% increase in AUC in females. Adjusting for body weight decreases the magnitude of the differences seen. </p>    <p> <span class="Bold">Pediatric:</span> </p>    <p>Pharmacokinetic data in the pediatric population are not available. </p>    <p> <span class="Bold">Drug-Drug Interactions:</span> </p>    <p>Data from drug-drug interactions studies involving coadministration of gemfibrozil, niacin, itraconazole, erythromycin, tolbutamide or clopidogrel indicate that the PK disposition of fluvastatin is not significantly altered when fluvastatin is coadministered with any of these drugs. </p>    <p>The below listed drug interaction information is derived from studies using fluvastatin capsules. </p>    <a name="id_d04324f3-dfca-4847-aa2a-652c9700077a"></a>    <div class="scrollingtable">    <table width="443">      <caption>       <span>Table 3: Effect of Coadministered Drugs on Fluvastatin Systemic Exposure</span>      </caption>      <colgroup>      <col width="29.7%" />       <col width="26.4%" />       <col width="22.3%" />       <col width="21.5%" />      </colgroup>     <tfoot>       <tr>        <td align="left" colspan="4">         <dl class="Footnote">          <dt>           <a href="#footnote-reference-2" name="footnote-2">*</a>          </dt>          <dd>          Single dose unless otherwise noted          </dd>          <dt>           <a href="#footnote-reference-3" name="footnote-3"></a>          </dt>          <dd>          Mean ratio (with/without coadministered drug and no change = 1 fold) or % change (with/without coadministered drug and no change = 0%); symbols of  and  indicate the exposure increase and decrease, respectively.          </dd>          <dt>           <a href="#footnote-reference-4" name="footnote-4"></a>          </dt>          <dd>          Considered clinically significant [          <span class="Italics">see Dosage and Administration (<a href="#i4i_dosage_admin_id_0e871e12-e843-4361-9579-7763e877f9bf">2</a>) and Drug Interactions (<a href="#i4i_interactions_id_25d02351-69fd-4e29-9276-8e0b77bc6752">7</a>)</span>]         </dd>         </dl> </td>       </tr>      </tfoot>      <tbody class="Headless">       <tr class="First Toprule">        <td class="Botrule Rrule" align="left" valign="top">Coadministered drug and dosing regimen</td>       <td class="Botrule Rrule" align="left" valign="top">Fluvastatin </td>       <td class="Botrule Rrule" align="left" valign="top"></td>       <td class="Botrule" align="left" valign="top"></td>       </tr>       <tr>        <td class="Botrule Rrule" align="left" valign="top"></td>       <td class="Botrule Rrule" align="left" valign="top"><span class="Bold">Dose (mg)</span><a class="Sup" href="#footnote-2" name="footnote-reference-2">*</a></td>       <td class="Botrule Rrule" align="left" valign="top"><span class="Bold">Change in AUC</span><a class="Sup" href="#footnote-3" name="footnote-reference-3"></a></td>       <td class="Botrule" align="left" valign="top"><span class="Bold">Change in C<span class="Sub">max</span></span><a class="Sup" href="#footnote-3"></a></td>       </tr>       <tr>        <td class="Botrule Rrule" align="left" valign="top">Cyclosporine - stable dose (b.i.d.)<a class="Sup" href="#footnote-4" name="footnote-reference-4"></a></td>       <td class="Botrule Rrule" align="left" valign="top">20 mg QD for 14 weeks</td>       <td class="Botrule Rrule" align="left" valign="top">90%</td>       <td class="Botrule" align="left" valign="top">30%</td>       </tr>       <tr>        <td class="Botrule Rrule" align="left" valign="top">Fluconazole 400 mg QD day 1,200 mg b.i.d. day 2 to 4<a class="Sup" href="#footnote-4"></a></td>       <td class="Botrule Rrule" align="left" valign="top">40 mg QD</td>       <td class="Botrule Rrule" align="left" valign="top">84%</td>       <td class="Botrule" align="left" valign="top">44%</td>       </tr>       <tr>        <td class="Botrule Rrule" align="left" valign="top">Cholestyramine 8 g QD</td>       <td class="Botrule Rrule" align="left" valign="top">20 mg QD administered 4 hrs after a meal plus cholestyramine</td>       <td class="Botrule Rrule" align="left" valign="top">51%</td>       <td class="Botrule" align="left" valign="top">83%</td>       </tr>       <tr>        <td class="Botrule Rrule" align="left" valign="top">Rifampicin 600 mg QD for 6 days</td>       <td class="Botrule Rrule" align="left" valign="top">20 mg QD</td>       <td class="Botrule Rrule" align="left" valign="top">53%</td>       <td class="Botrule" align="left" valign="top">42%</td>       </tr>       <tr>        <td class="Botrule Rrule" align="left" valign="top">Cimetidine 400 mg b.i.d. for 5 days, QD on Day 6</td>       <td class="Botrule Rrule" align="left" valign="top">20 mg QD</td>       <td class="Botrule Rrule" align="left" valign="top">30%</td>       <td class="Botrule" align="left" valign="top">40%</td>       </tr>       <tr>        <td class="Botrule Rrule" align="left" valign="top">Ranitidine 150 mg b.i.d. for 5 days, QD on Day 6</td>       <td class="Botrule Rrule" align="left" valign="top">20 mg QD</td>       <td class="Botrule Rrule" align="left" valign="top">10%</td>       <td class="Botrule" align="left" valign="top">50%</td>       </tr>       <tr>        <td class="Botrule Rrule" align="left" valign="top">Omeprazole 40 mg QD for 6 days</td>       <td class="Botrule Rrule" align="left" valign="top">20 mg QD</td>       <td class="Botrule Rrule" align="left" valign="top">20%</td>       <td class="Botrule" align="left" valign="top">37%</td>       </tr>       <tr>        <td class="Botrule Rrule" align="left" valign="top">Phenytoin 300 mg QD</td>       <td class="Botrule Rrule" align="left" valign="top">40 mg b.i.d. for 5 days</td>       <td class="Botrule Rrule" align="left" valign="top">40%</td>       <td class="Botrule" align="left" valign="top">27%</td>       </tr>       <tr>        <td class="Botrule Rrule" align="left" valign="top">Propranolol 40 mg b.i.d. for 3.5 days</td>       <td class="Botrule Rrule" align="left" valign="top">40 mg QD</td>       <td class="Botrule Rrule" align="left" valign="top">5%</td>       <td class="Botrule" align="left" valign="top">No change</td>       </tr>       <tr>        <td class="Botrule Rrule" align="left" valign="top">Digoxin 0.1 to 0.5 mg QD for 3 weeks</td>       <td class="Botrule Rrule" align="left" valign="top">40 mg QD</td>       <td class="Botrule Rrule" align="left" valign="top">No change</td>       <td class="Botrule" align="left" valign="top">11%</td>       </tr>       <tr>        <td class="Botrule Rrule" align="left" valign="top">Diclofenac 25 mg QD</td>       <td class="Botrule Rrule" align="left" valign="top">40 mg QD for 8 days</td>       <td class="Botrule Rrule" align="left" valign="top">50%</td>       <td class="Botrule" align="left" valign="top">80%</td>       </tr>       <tr>        <td class="Botrule Rrule" align="left" valign="top">Glyburide 5 to 20 mg QD for 22 days</td>       <td class="Botrule Rrule" align="left" valign="top">40 mg b.i.d. for 14 days</td>       <td class="Botrule Rrule" align="left" valign="top">51%</td>       <td class="Botrule" align="left" valign="top">44%</td>       </tr>       <tr>        <td class="Botrule Rrule" align="left" valign="top">Warfarin 30 mg QD</td>       <td class="Botrule Rrule" align="left" valign="top">40 mg QD for 8 days</td>       <td class="Botrule Rrule" align="left" valign="top">30%</td>       <td class="Botrule" align="left" valign="top">67%</td>       </tr>       <tr class="Botrule Last">        <td class="Rrule" align="left" valign="top">Clopidogrel 300 mg loading dose on day 10, 75 mg QD on days 11 to 19</td>       <td class="Rrule" align="left" valign="top">fluvastatin sodium extended-release tablets, 80 mg QD for 19 days </td>       <td class="Rrule" align="left" valign="top">2%</td>       <td align="left" valign="top">27%</td>       </tr>      </tbody>     </table>   </div>    <p>Data from drug-drug interaction studies involving fluvastatin and coadministration of either gemfibrozil, tolbutamide or losartan indicate that the PK disposition of either gemfibrozil, tolbutamide or losartan is not significantly altered when coadministered with fluvastatin. </p>    <a name="id_1ee97325-86e7-45a1-bcb8-18d80ea63b54"></a>    <div class="scrollingtable">    <table border="single" width="446">      <caption>       <span>Table 4: Effect of Fluvastatin Coadministration on Systemic Exposure of Other Drugs</span>      </caption>      <colgroup>      <col width="29.5%" />       <col width="28.3%" />       <col width="22.2%" />       <col width="20.2%" />      </colgroup>     <tfoot>       <tr>        <td align="left" colspan="4">         <dl class="Footnote">          <dt>           <a href="#footnote-reference-5" name="footnote-5">*</a>          </dt>          <dd>          Single dose unless otherwise noted         </dd>          <dt>           <a href="#footnote-reference-6" name="footnote-6"></a>          </dt>          <dd>          Mean ratio (with/without coadministered drug and no change = 1 fold) or % change (with/without coadministered drug and no change = 0%); symbols of  and  indicate the exposure increase and decrease, respectively.          </dd>          <dt>           <a href="#footnote-reference-7" name="footnote-7"></a>          </dt>          <dd>          Considered clinically significant [          <span class="Italics">see Dosage and Administration (<a href="#i4i_dosage_admin_id_0e871e12-e843-4361-9579-7763e877f9bf">2</a>) and Drug Interactions (<a href="#i4i_interactions_id_25d02351-69fd-4e29-9276-8e0b77bc6752">7</a>)</span>]&nbsp;          </dd>         </dl> </td>       </tr>      </tfoot>      <tbody class="Headless">       <tr class="First">        <td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Fluvastatin dosage regimen</td>       <td class="Botrule Rrule" align="left" valign="top">Coadministered drug</td>       <td class="Botrule Rrule" align="left" valign="top"></td>       <td class="Botrule Rrule" align="left" valign="top"></td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="left" valign="top"></td>       <td class="Botrule Rrule" align="left" valign="top"><span class="Bold">Name and Dose (mg)</span><a class="Sup" href="#footnote-5" name="footnote-reference-5">*</a></td>       <td class="Botrule Rrule" align="left" valign="top"><span class="Bold">Change in AUC</span><a class="Sup" href="#footnote-6" name="footnote-reference-6"></a></td>       <td class="Botrule Rrule" align="left" valign="top"><span class="Bold">Change in C<span class="Sub">max</span></span><a class="Sup" href="#footnote-6"></a></td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="left" valign="top">40 mg QD for 5 days</td>       <td class="Botrule Rrule" align="left" valign="top">Phenytoin 300 mg QD<a class="Sup" href="#footnote-7" name="footnote-reference-7"></a></td>       <td class="Botrule Rrule" align="left" valign="top">20%</td>       <td class="Botrule Rrule" align="left" valign="top">5%</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="left" valign="top">40 mg b.i.d. for 21 days</td>       <td class="Botrule Rrule" align="left" valign="top">Glyburide 5 to 20 mg QD for 22 days<a class="Sup" href="#footnote-7"></a></td>       <td class="Botrule Rrule" align="left" valign="top">70%</td>       <td class="Botrule Rrule" align="left" valign="top">50%</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="left" valign="top">40 mg QD for 8 days</td>       <td class="Botrule Rrule" align="left" valign="top">Diclofenac 25 mg QD</td>       <td class="Botrule Rrule" align="left" valign="top">25%</td>       <td class="Botrule Rrule" align="left" valign="top">60%</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="left" valign="top">40 mg QD for 8 days</td>       <td class="Botrule Rrule" align="left" valign="top">Warfarin 30 mg QD</td>       <td class="Botrule Rrule" align="left" valign="top">S-warfarin: 7%</td>       <td class="Botrule Rrule" align="left" valign="top">S-warfarin: 10%</td>       </tr>       <tr class="Last">        <td class="Botrule Lrule Rrule" align="left" valign="top"></td>       <td class="Botrule Rrule" align="left" valign="top"></td>       <td class="Botrule Rrule" align="left" valign="top">R-warfarin: no change</td>       <td class="Botrule Rrule" align="left" valign="top">R-warfarin: 6%</td>       </tr>      </tbody>     </table>   </div>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">13 NONCLINICAL TOXICOLOGY</a> <div class="Section toggle-content closed" data-sectioncode="43680-8">   <a name="i4i_nonclinical_toxicology_id_13cd65f0-5db7-4669-a1bd-009e40fef828"></a>  <a name="section-12"></a>   <p></p>    <div class="Section" data-sectioncode="34083-6">    <a name="i4i_carcinogenesis_mutagenesis_fertility_id_eec5a703-5537-45db-974b-efc4f8d860f4"></a>   <a name="section-12.1"></a>    <p></p>    <h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>    <p class="First">A 2 year study was performed in rats at dose levels of 6, 9, and 18 to 24 (escalated after 1 year) mg/kg/day. These treatment levels represented plasma drug levels of approximately 9, 13, and 26 to 35 times the mean human plasma drug concentration after a 40 mg oral dose. A low incidence of forestomach squamous papillomas and 1 carcinoma of the forestomach at the 24 mg/kg/day dose level was considered to reflect the prolonged hyperplasia induced by direct contact exposure to fluvastatin sodium rather than to a systemic effect of the drug. In addition, an increased incidence of thyroid follicular cell adenomas and carcinomas was recorded for males treated with 18 to 24 mg/kg/day. The increased incidence of thyroid follicular cell neoplasm in male rats with fluvastatin sodium appears to be consistent with findings from other HMG-CoA reductase inhibitors. In contrast to other HMG-CoA reductase inhibitors, no hepatic adenomas or carcinomas were observed. </p>    <p>The carcinogenicity study conducted in mice at dose levels of 0.3, 15 and 30 mg/kg/day revealed, as in rats, a statistically significant increase in forestomach squamous cell papillomas in males and females at 30 mg/kg/day and in females at 15 mg/kg/day. These treatment levels represented plasma drug levels of approximately 0.05, 2, and 7 times the mean human plasma drug concentration after a 40 mg oral dose. </p>    <p>No evidence of mutagenicity was observed <span class="Italics">in vitro</span>, with or without rat-liver metabolic activation, in the following studies: microbial mutagen tests using mutant strains of <span class="Italics">Salmonella typhimurium </span>or <span class="Italics">Escherichia coli</span>; malignant transformation assay in BALB/3T3 cells; unscheduled DNA synthesis in rat primary hepatocytes; chromosomal aberrations in V79 Chinese Hamster cells; HGPRT V79 Chinese Hamster cells. In addition, there was no evidence of mutagenicity <span class="Italics">in vivo</span> in either a rat or mouse micronucleus test. </p>    <p>In a study in rats at dose levels for females of 0.6, 2, and 6 mg/kg/day and at dose levels for males of 2, 10 and 20 mg/kg/day, fluvastatin sodium had no adverse effects on the fertility or reproductive performance. </p>    <p>Seminal vesicles and testes were small in hamsters treated for 3 months at 20 mg/kg/day (approximately three times the 40 mg human daily dose based on surface area, mg/m<span class="Sup">2</span>). There was tubular degeneration and aspermatogenesis in testes as well as vesiculitis of seminal vesicles. Vesiculitis of seminal vesicles and edema of the testes were also seen in rats treated for 2 years at 18 mg/kg/day (approximately 4 times the human C<span class="Sub">max</span> achieved with a 40 mg daily dose). </p>    <p>Fluvastatin sodium produced delays in skeletal development in rats at doses of 12 mg/kg/day and in rabbits at doses of 10 mg/kg/day. Malaligned thoracic vertebrae were seen in rats at 36 mg/kg, a dose that produced maternal toxicity. These doses resulted in 2 times (rat at 12 mg/kg) or 5 times (rabbit at 10 mg/kg) the 40 mg human exposure based on mg/m<span class="Sup">2</span> surface area. A study in which female rats were dosed during the third trimester at 12 and 24 mg/kg/day resulted in maternal mortality at or near term and postpartum. In addition, fetal and neonatal lethality were apparent. No effects on the dam or fetus occurred at 2 mg/kg/day. A second study at levels of 2, 6, 12 and 24 mg/kg/day confirmed the findings in the first study with neonatal mortality beginning at 6 mg/kg. A modified Segment III study was performed at dose levels of 12 or 24 mg/kg/day with or without the presence of concurrent supplementation with mevalonic acid, a product of HMG-CoA reductase which is essential for cholesterol biosynthesis. The concurrent administration of mevalonic acid completely prevented the maternal and neonatal mortality but did not prevent low body weights in pups at 24 mg/kg on days 0 and 7 postpartum. </p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">14 CLINICAL STUDIES</a> <div class="Section toggle-content closed" data-sectioncode="34092-7">   <a name="i4i_clinical_studies_id_178aed6d-69ac-4787-8bdf-67ed85e0a728"></a>  <a name="section-13"></a>   <p></p>    <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_004900ac-e885-48ae-bdef-5017fb4ff4bc"></a>   <a name="section-13.1"></a>    <p></p>    <h2>14.1 Hypercholesterolemia (Heterozygous Familial and Nonfamilial) and Mixed Dyslipidemia</h2>    <p class="First">In 12 placebo-controlled studies in patients with primary hypercholesterolemia and mixed dyslipidemia, fluvastatin capsules were administered to 1621 patients in daily dose regimens of 20 mg, 40 mg, and 80 mg (40 mg twice daily) for at least 6 weeks duration (<span class="Bold">Table 5</span>). After 24 weeks of treatment, treatment with fluvastatin capsules resulted in significantly reduced plasma LDL-C, TC, TG, and Apo B compared to placebo and was associated with variable increases in HDL-C across the dose range. </p>    <p>In patients with primary mixed dyslipidemia as defined by baseline plasma TG levels  200 mg/dL and &lt; 400 mg/dL, treatment with fluvastatin capsules produced significant decreases in Total-C, LDL-C, TG and Apo B and variable increases in HDL-C (<span class="Bold">Table 5</span>). </p>    <a name="id_a394b7bd-9b85-40d2-91e5-defd4541b427"></a>    <div class="scrollingtable">    <table border="single" width="448">      <caption>       <span>Table 5: Median Percent Change in Lipid Parameters From Baseline to Week 24 Endpoint all Placebo-Controlled Studies (Fluvastatin Capsules) </span>      </caption>      <colgroup>      <col width="28.6%" />       <col width="7.6%" />       <col width="7.6%" />       <col width="7.6%" />       <col width="7.6%" />       <col width="7.6%" />       <col width="6.3%" />       <col width="6.9%" />       <col width="7.6%" />       <col width="7.6%" />       <col width="5.1%" />      </colgroup>     <tfoot>       <tr>        <td align="left" colspan="11">         <dl class="Footnote">          <dt>           <a href="#footnote-reference-8" name="footnote-8">*</a>          </dt>          <dd>          Data for fluvastatin capsules from 12 placebo-controlled trials         </dd>         </dl> </td>       </tr>      </tfoot>      <tbody class="Headless">       <tr class="First Toprule">        <td align="left" valign="top"></td>       <td class="Toprule" align="center" colspan="2" valign="top"><span class="Bold">Total Chol</span></td>       <td class="Toprule" align="center" colspan="2" valign="top"><span class="Bold">TG</span></td>       <td class="Toprule" align="center" colspan="2" valign="top"><span class="Bold">LDL</span></td>       <td class="Toprule" align="center" colspan="2" valign="top"><span class="Bold">Apo B</span></td>       <td align="center" colspan="2" valign="top"><span class="Bold">HDL</span></td>       </tr>       <tr>        <td class="Botrule" align="left" valign="top"><span class="Bold">Dose</span></td>       <td class="Botrule" align="center" valign="top"><span class="Bold">N</span></td>       <td class="Botrule" align="center" valign="top"><span class="Bold">% </span></td>       <td class="Botrule" align="center" valign="top"><span class="Bold">N</span></td>       <td class="Botrule" align="center" valign="top"><span class="Bold">% </span></td>       <td class="Botrule" align="center" valign="top"><span class="Bold"> N </span></td>       <td class="Botrule" align="left" valign="top"><span class="Bold">%</span><span class="Bold"> </span></td>       <td class="Botrule" align="center" valign="top"><span class="Bold">N</span></td>       <td class="Botrule" align="center" valign="top"><span class="Bold">% </span></td>       <td class="Botrule" align="center" valign="top"><span class="Bold">N</span></td>       <td class="Botrule" align="left" valign="top"><span class="Bold">% </span></td>       </tr>       <tr>        <td align="left" valign="top"> <p class="First">All Patients</p> fluvastatin capsules 20 mg<a class="Sup" href="#footnote-8" name="footnote-reference-8">*</a></td>       <td align="center" valign="top">747</td>       <td align="center" valign="top">-17</td>       <td align="center" valign="top">747</td>       <td align="center" valign="top">-12</td>       <td align="center" valign="top">747</td>       <td align="center" valign="top">-22</td>       <td align="center" valign="top">114</td>       <td align="center" valign="top">-19</td>       <td align="center" valign="top">747</td>       <td align="center" valign="top">+3</td>       </tr>       <tr>        <td align="left" valign="top"> fluvastatin capsules 40 mg<a class="Sup" href="#footnote-8">*</a></td>       <td align="center" valign="top">748</td>       <td align="center" valign="top">-19</td>       <td align="center" valign="top">748</td>       <td align="center" valign="top">-14</td>       <td align="center" valign="top">748</td>       <td align="center" valign="top">-25</td>       <td align="center" valign="top">125</td>       <td align="center" valign="top">-18</td>       <td align="center" valign="top">748</td>       <td align="center" valign="top">+4</td>       </tr>       <tr>        <td align="left" valign="top"> <p class="First"> fluvastatin capsules 40 mg twice daily<a class="Sup" href="#footnote-8">*</a> </p> </td>       <td align="center" valign="top">257</td>       <td align="center" valign="top">-27</td>       <td align="center" valign="top">257</td>       <td align="center" valign="top">-18</td>       <td align="center" valign="top">257</td>       <td align="center" valign="top">-36</td>       <td align="center" valign="top">232</td>       <td align="center" valign="top">-28</td>       <td align="center" valign="top">257</td>       <td align="center" valign="top">+6</td>       </tr>       <tr>        <td align="left" valign="top"> <p class="First">Baseline TG  200 mg/dL</p> fluvastatin capsules 20 mg<a class="Sup" href="#footnote-8">*</a></td>       <td align="center" valign="top">148</td>       <td align="center" valign="top">-16</td>       <td align="center" valign="top">148</td>       <td align="center" valign="top">-17</td>       <td align="center" valign="top">148</td>       <td align="center" valign="top">-22</td>       <td align="center" valign="top">23</td>       <td align="center" valign="top">-19</td>       <td align="center" valign="top">148</td>       <td align="center" valign="top">+6</td>       </tr>       <tr>        <td align="left" valign="top"> fluvastatin capsules 40 mg<a class="Sup" href="#footnote-8">*</a></td>       <td align="center" valign="top">179</td>       <td align="center" valign="top">-18</td>       <td align="center" valign="top">179</td>       <td align="center" valign="top">-20</td>       <td align="center" valign="top">179</td>       <td align="center" valign="top">-24</td>       <td align="center" valign="top">47</td>       <td align="center" valign="top">-18</td>       <td align="center" valign="top">179</td>       <td align="center" valign="top">+7</td>       </tr>       <tr class="Last">        <td class="Botrule" align="left" valign="top"> fluvastatin capsules 40 mg twice daily<a class="Sup" href="#footnote-8">*</a></td>       <td class="Botrule" align="center" valign="top">76</td>       <td class="Botrule" align="center" valign="top">-27</td>       <td class="Botrule" align="center" valign="top">76</td>       <td class="Botrule" align="center" valign="top">-23</td>       <td class="Botrule" align="center" valign="top">76</td>       <td class="Botrule" align="center" valign="top">-35</td>       <td class="Botrule" align="center" valign="top">69</td>       <td class="Botrule" align="center" valign="top">-28</td>       <td class="Botrule" align="center" valign="top">76</td>       <td class="Botrule" align="center" valign="top">+9</td>       </tr>      </tbody>     </table>   </div>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_e9d04278-739f-4353-bf70-63bcb840b447"></a>   <a name="section-13.2"></a>    <p></p>    <h2>14.2 Heterozygous Familial Hypercholesterolemia in Pediatric Patients</h2>    <p class="First">Fluvastatin capsules were studied in two open-label, uncontrolled, dose-titration studies. The first study enrolled 29 pre-pubertal boys, 9 to 12 years of age, who had an LDL-C level &gt; 90th percentile for age and one parent with primary hypercholesterolemia and either a family history of premature ischemic heart disease or tendon xanthomas. The mean baseline LDL-C was 226 mg/dL (range: 137 to 354 mg/dL). All patients were started on fluvastatin capsules, 20 mg daily with dose adjustments every 6 weeks to 40 mg daily then 80 mg daily (40 mg b.i.d.) to achieve an LDL-C goal between 96.7 to 123.7 mg/dL. Endpoint analyses were performed at Year 2. Fluvastatin capsules decreased plasma levels of Total-C and LDL-C by 21% and 27%, respectively. The mean achieved LDL-C was 161 mg/dL (range: 74 to 336 mg/dL). </p>    <p>The second study enrolled 85 male and female patients, 10 to 16 years of age, who had an LDL-C &gt; 190 mg/dL or LDL-C &gt; 160 mg/dL and one or more risk factors for coronary heart disease, or LDL-C &gt; 160 mg/dL and a proven LDL-receptor defect. The mean baseline LDL-C was 225 mg/dL (range: 148 to 343 mg/dL). All patients were started on fluvastatin capsules 20 mg daily with dose adjustments every 6 weeks to 40 mg daily then 80 mg daily (fluvastatin sodium extended-release tablets, 80 mg) to achieve an LDL-C goal of &lt; 130 mg/dL. Endpoint analyses were performed at Week 114. Fluvastatin sodium decreased plasma levels of Total-C and LDL-C by 22% and 28%, respectively. The mean achieved LDL-C was 159 mg/dL (range: 90 to 295 mg/dL). </p>    <p>The majority of patients in both studies (83% in the first study and 89% in the second study) were titrated to the maximum daily dose of 80 mg. At study endpoint, 26% to 30% of patients in both studies achieved a targeted LDL-C goal of &lt; 130 mg/dL. The long-term efficacy of fluvastatin sodium therapy in childhood to reduce morbidity and mortality in adulthood has not been established. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_f11bada3-f904-4a49-b5db-5276fee36772"></a>   <a name="section-13.3"></a>    <p></p>    <h2>14.3 Secondary Prevention of Cardiovascular Disease</h2>    <p class="First">In the Fluvastatin Capsules Intervention Prevention Study, the effect of fluvastatin capsules, 40 mg administered twice daily on the risk of recurrent cardiac events (time to first occurrence of cardiac death, nonfatal myocardial infarction, or revascularization) was assessed in 1677 patients with CHD who had undergone a percutaneous coronary intervention (PCI) procedure (mean time from PCI to randomization = 3 days). In this multicenter, randomized, double-blind, placebo-controlled study, patients were treated with dietary/lifestyle counseling and either fluvastatin capsules, 40 mg (n = 844) or placebo (n = 833) given twice daily for a median of 3.9 years. The study population was 84% male, 98% Caucasian, with 37% &gt; 65 years of age. Mean baseline lipid concentrations were: total cholesterol 201 mg/dL, LDL-C 132 mg/dL, triglycerides 70 mg/dL and HDL-C 39 mg/dL. </p>    <p>Fluvastatin capsules significantly reduced the risk of recurrent cardiac events (<span class="Bold">Figure 1</span>) by 22% (p = 0.013, 181 patients in the fluvastatin capsules group vs. 222 patients in the placebo group). Revascularization procedures comprised the majority of the initial recurrent cardiac events (143 revascularization procedures in the fluvastatin capsules group and 171 in the placebo group). Consistent trends in risk reduction were observed in patients &gt; 65 years of age. </p>    <div class="Figure">     <img src="image.cfm?setid=aad8b373-0aec-4efb-8e61-3d8114b31127&name=acd656cf%2D3edc%2D499c%2D9630%2D17ac45753572%2D02%2Ejpg" alt="Figure 1. Primary Endpoint - Recurrent Cardiac Events (Cardiac Death, Nonfatal MI or Revascularization Procedure) (ITT Population)" />    <p class="MultiMediaCaption">Figure 1: Primary Endpoint - Recurrent Cardiac Events (Cardiac Death, Nonfatal MI or Revascularization Procedure) (ITT Population)</p>    </div>    <p>Outcome data for the Fluvastatin Capsules Intervention Prevention Study are shown in <span class="Bold">Figure 2</span>. After exclusion of revascularization procedures (CABG and repeat PCI) occurring within the first 6 months of the initial procedure involving the originally instrumental site, treatment with fluvastatin capsules was associated with a 32% (p = 0.002) reduction in risk of late revascularization procedures (CABG or PCI occurring at the original site &gt; 6 months after the initial procedure, or at another site). </p>    <div class="Figure">     <img src="image.cfm?setid=aad8b373-0aec-4efb-8e61-3d8114b31127&name=acd656cf%2D3edc%2D499c%2D9630%2D17ac45753572%2D03%2Ejpg" alt="Figure 2. Fluvastatin Capsules INtervention Prevention Study - Primary and SEcondary Endpoints" />    <p class="MultiMediaCaption">Figure 2: Fluvastatin Capsules Intervention Prevention Study - Primary and Secondary Endpoints</p>    </div>    <p>In the Lipoprotein and Coronary Atherosclerosis Study (LCAS), the effect of fluvastatin capsule therapy on coronary atherosclerosis was assessed by quantitative coronary angiography (QCA) in patients with CAD and mild to moderate hypercholesterolemia (baseline LDL-C range 115 to 190 mg/dL). In this randomized double-blind, placebo-controlled trial, 429 patients were treated with conventional measures (Step 1 AHA Diet) and either fluvastatin capsules, 40 mg/day or placebo. In order to provide treatment to patients receiving placebo with LDL-C levels  160 mg/dL at baseline, adjunctive therapy with cholestyramine was added after Week 12 to all patients in the study with baseline LDL-C values of  160 mg/dL which were present in 25% of the study population. Quantitative coronary angiograms were evaluated at baseline and 2.5 years in 340 (79%) angiographic evaluable patients. </p>    <p>Compared to placebo, fluvasatin capsules significantly slowed the progression of coronary atherosclerosis as measured by within-patient per-lesion change in minimum lumen diameter (MLD), the primary endpoint (<span class="Bold">Figure 3</span> below), percent diameter stenosis (<span class="Bold">Figure 4</span>), and the formation of new lesions (13% of all fluvastatin patients versus 22% of all placebo patients). A significant difference in favor of fluvastatin capsules was found between all fluvastatin and all placebo patients in the distribution among the three categories of definite progression, definite regression, and mixed or no change. Beneficial angiographic results (change in MLD) were independent of patients gender and consistent across a range of baseline LDL-C levels. </p>    <div class="Figure">     <img src="image.cfm?setid=aad8b373-0aec-4efb-8e61-3d8114b31127&name=acd656cf%2D3edc%2D499c%2D9630%2D17ac45753572%2D04%2Ejpg" alt="Figure 3. Change in Minimum Lumen Diameter (mm)" />    <p class="MultiMediaCaption">Figure 3: Change in Minimum Lumen Diameter (mm)</p>    </div>    <div class="Figure">     <img src="image.cfm?setid=aad8b373-0aec-4efb-8e61-3d8114b31127&name=acd656cf%2D3edc%2D499c%2D9630%2D17ac45753572%2D05%2Ejpg" alt="Figure 4. Change in % Diameter Stenosis" />    <p class="MultiMediaCaption">Figure 4: Change in % Diameter Stenosis</p>    </div>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">15 REFERENCES</a> <div class="Section toggle-content closed" data-sectioncode="34093-5">   <a name="i4i_references_id_c0892fd3-ccb4-4a9e-b75d-ebf0ace9e5fd"></a>  <a name="section-14"></a>   <p></p>    <ol>    <li>National Cholesterol Education Program (NCEP): Highlights of the Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. <span class="Italics">Pediatrics</span>. 89(3):495-501.1992. </li>    <li>Manson, J.M., Freyssinges, C., Ducrocq, M.B., Stephenson, W.P., Postmarketing Surveillance of Lovastatin and Simvastatin Exposure During Pregnancy, <span class="Italics">Reproductive Toxicology, </span>10(6): 439-446, 1996. </li>   </ol>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">16 HOW SUPPLIED/STORAGE AND HANDLING</a> <div class="Section toggle-content closed" data-sectioncode="34069-5">   <a name="i4i_how_supplied_id_e8b90606-1d19-4577-854a-0ec52d6f3fb7"></a>  <a name="section-15"></a>   <p></p>    <p class="First">Fluvastatin capsules USP are available as follows:</p>   <p>20 mg - hard gelatin capsules with ivory opaque body and pink opaque cap, filled with an off-white to yellowish powder with small agglomerates, body imprinted with TEVA and cap imprinted with 7442, in bottles of 30 and 100.</p>   <p>40 mg - hard gelatin capsules with yellow opaque body and pink opaque cap, filled with an off-white to yellowish powder with small agglomerates, body imprinted with TEVA and cap imprinted with 7443, in bottles of 30 and 100.</p>   <div class="Section" data-sectioncode="44425-7">    <a name="i4i_storage_id_b926a2e1-7f0a-4a93-8d9a-119dfccaf03c"></a>   <a name="section-15.1"></a>    <p></p>    <h2>Store and Dispense</h2>    <p class="First">Store at 20&deg; to 25&deg;C (68&deg; to 77&deg;F) [See USP Controlled Room Temperature].</p>    <p>Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required). Protect from light.</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">17 PATIENT COUNSELING INFORMATION</a> <div class="Section toggle-content closed" data-sectioncode="34076-0">   <a name="i4i_info_patients_id_e617cb73-94d5-4a8f-9bb3-cbbcebbb10b2"></a>  <a name="section-16"></a>   <p></p>    <p class="First"> <span class="Bold">Information for Patients</span> </p>   <p>Patients taking fluvastatin capsules should be advised that high cholesterol is a chronic condition and they should adhere to their medication along with their National Cholesterol Education Program (NCEP)-recommended diet, a regular exercise program, and periodic testing of a fasting lipid panel to determine goal attainment. </p>   <p> <span class="Bold">Patients should be advised about substances they should not take concomitantly with fluvastatin capsules [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_e04b0745-ab1b-4bfc-b72e-ea8713c0a247">5.1</a>)</span>]. Patients should also be advised to inform other healthcare professionals prescribing a new medication that they are taking fluvastatin capsules. </span> </p>   <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_450aad5d-ef43-483b-a899-96bfd6f025f5"></a>   <a name="section-16.1"></a>    <p></p>    <h2>17.1 Muscle Pain</h2>    <p class="First">Patients starting therapy with fluvastatin capsules should be advised of the risk of myopathy and told to report promptly any unexplained muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever or if these muscle signs or symptoms persist after discontinuing fluvastatin. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_bbdcf00c-57b6-4c1c-beca-9bcb629f9d9c"></a>   <a name="section-16.2"></a>    <p></p>    <h2>17.2 Liver Enzymes</h2>    <p class="First">It is recommended that liver enzyme tests be performed before the initiation of fluvastatin capsules and if signs or symptoms of liver injury occur. All patients treated with fluvastatin capsules should be advised to report promptly any symptoms that may indicate liver injury, including fatigue, anorexia, right upper abdominal discomfort, dark urine or jaundice. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_43878ff2-5235-4a5d-8dbe-65767aab3334"></a>   <a name="section-16.3"></a>    <p></p>    <h2>17.3 Pregnancy</h2>    <p class="First">Women of childbearing age should be advised to use an effective method of birth control to prevent pregnancy while using fluvastatin capsules. Discuss future pregnancy plans with your patients, and discuss when to stop taking fluvastatin capsules if they are trying to conceive. Patients should be advised that if they become pregnant they should stop taking fluvastatin capsules and call their healthcare professional. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_77498f5f-2071-4316-b6d5-7f2f8cb26388"></a>   <a name="section-16.4"></a>    <p></p>    <h2>17.4 Breastfeeding</h2>    <p class="First">Women who are breastfeeding should not use fluvastatin capsules. Patients who have a lipid disorder and are breastfeeding should be advised to discuss the options with their healthcare professional.</p>    <p>Manufactured In Israel By:</p>    <p> <span class="Bold">TEVA PHARMACEUTICAL IND. LTD.</span> </p>    <p>Jerusalem, 91010, Israel</p>    <p>Manufactured For:</p>    <p> <span class="Bold">TEVA PHARMACEUTICALS USA</span> </p>    <p>Sellersville, PA 18960</p>    <p>Rev C. 11/2012</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">PATIENT PACKAGE INSERT</a> <div class="Section toggle-content closed" data-sectioncode="42230-3">   <a name="i4i_patient_package_insert_id_539ba255-43c9-4431-827f-b382849496b7"></a>  <a name="section-17"></a>   <p></p>   <p class="First"> <span class="Bold">FDA-Approved Patient Labeling </span> </p>   <p> <span class="Bold">Fluvastatin Capsules USP</span> </p>   <p> <span class="Bold"> 20 mg, 40 mg</span> </p>   <p> <span class="Bold">You must read and follow all instructions before using fluvastatin capsules. </span> </p>   <p>Read the Patient Information every time you or a family member gets fluvastatin capsules. There may be new information. This Patient Information does not take the place of talking with your doctor about your medical condition or treatment. If you have any questions about fluvastatin capsules, ask your doctor or pharmacist.</p>   <p> <span class="Bold">What are fluvastatin capsules? </span> </p>   <p>Fluvastatin capsules are a prescription medicine called &quot;statins&quot; that lower cholesterol in your blood. They lower the &quot;bad&quot; cholesterol and triglycerides in your blood. They can raise your &quot;good&quot; cholesterol as well. </p>   <p>Fluvastatin capsules are for people whose cholesterol does not come down enough with exercise and a low-fat diet alone. </p>   <p>Fluvastatin capsules may be used in patients with heart disease (coronary artery disease) to: </p>   <ul>    <li>lower the chances of heart problems which would require procedures to help restore blood flow to the heart. </li>    <li>slow the buildup of too much cholesterol in the arteries of the heart. </li>   </ul>   <p>Treatment with fluvastatin capsules has not been shown to prevent heart attacks or stroke.</p>   <p>Fluvastatin capsules are taken one or two times a day. </p>   <p> <span class="Bold">Who should not take fluvastatin capsules? </span> </p>   <p> <span class="Bold">Do not take fluvastatin capsules if you: </span> </p>   <ul>    <li>are pregnant or think you may be pregnant, or are planning to become pregnant. Fluvastatin capsules may harm your unborn baby. If you get pregnant, stop taking fluvastatin capsules and call your doctor right away. </li>    <li>are breast-feeding. Fluvastatin sodium can pass into your breast milk and may harm your baby </li>    <li>have liver problems </li>    <li>are allergic to fluvastatin capsules or any of their ingredients. The active ingredient in fluvastatin capsules is fluvastatin. See the end of this leaflet for a complete list of ingredients in fluvastatin capsules. </li>   </ul>   <p>Fluvastatin capsules have not been studied in children under 9 years of age. </p>   <p> <span class="Bold">Before taking fluvastatin capsules, tell your doctor if you: </span> </p>   <ul>    <li>have muscle aches or weakness </li>    <li>drink more than 2 glasses of alcohol daily </li>    <li>have diabetes</li>    <li>have a thyroid problem </li>    <li>have kidney problems </li>   </ul>   <p>Some medicines should not be taken with fluvastatin capsules. Tell your doctor about all the medicines you take, including prescription and non-prescription medicines, vitamins and herbal supplements. Fluvastatin capsules and certain other medicines can interact causing serious side effects. Especially tell your doctor if you take medicines for: </p>   <ul>    <li>your immune system</li>    <li>cholesterol</li>    <li>infections</li>    <li>heart failure</li>    <li>seizures</li>    <li>diabetes</li>    <li>heartburn or stomach ulcers</li>   </ul>   <p>Know all the medicines you take. Keep a list of all the medicines you take with you to show your doctor and pharmacist. </p>   <p> <span class="Bold">How should I take fluvastatin capsules? </span> </p>   <ul>    <li>Your doctor will prescribe the medicine that is right for you. Take fluvastatin capsules exactly as prescribed. Do not change your dose or stop fluvastatin capsules without talking to your doctor. Your doctor may do blood tests to check your cholesterol levels during treatment with fluvastatin capsules. Your dose of fluvastatin capsules may be changed based on these blood test results. </li>    <li>Take fluvastatin capsules at the same time every evening. When fluvastatin capsules are taken twice daily, the capsules may be taken once in the morning and once in the evening. Fluvastatin capsules can be taken with or without food. </li>    <li>Do not open fluvastatin capsules. </li>    <li>Your doctor should start you on a low-fat and low-cholesterol diet before giving you fluvastatin capsules. Stay on this low-fat and low-cholesterol diet while taking fluvastatin capsules. </li>    <li>If you miss a dose of fluvastatin capsules, take it as soon as you remember. Do not take fluvastatin capsules if it has been more than 12 hours since your last dose. Wait and take the next dose at your regular time. Do not take 2 doses of fluvastatin capsules at the same time. </li>    <li>If you take too many fluvastatin capsules or overdose, call your doctor or Poison Control Center right away. Or, go to the nearest emergency room. </li>   </ul>   <p> <span class="Bold">What should I avoid while taking fluvastatin capsules? </span> </p>   <ul>    <li>Talk to your doctor before you start any new medicines. This includes prescription and nonprescription medicines, vitamins and herbal supplements. Fluvastatin capsules and certain other medicines can interact causing serious side effects. </li>    <li>Do not get pregnant. If you get pregnant, stop taking fluvastatin capsules right away and call your doctor. </li>   </ul>   <p> <span class="Bold">What are the possible side effects of fluvastatin capsules? </span> </p>   <p>When taking fluvastatin capsules, some patients may develop serious side effects, including: </p>   <p> <span class="Bold">muscle problems.</span> Call your health care professional right away if you experience unexplained muscle pain, tenderness, or weakness especially with fever. This may be an early sign of a rare muscle problem that could lead to serious kidney problems. </p>   <p>The risk of muscle problems is greater in people who are 65 years of age or older, or who already have thyroid or kidney problems. The chance of muscle problems may be increased if you are taking certain other medicines with fluvastatin capsules. </p>   <p>If you have muscle problems that do not go away even after your health care professional has advised you to stop taking fluvastatin capsules, notify your health care professional. Your health care professional may do further tests to diagnose the cause of your muscle problems.</p>   <p> <span class="Bold">liver problems</span>. Your doctor should do blood tests to check your liver before you start taking fluvastatin capsules, and if you have symptoms of liver problems while you take fluvastatin capsules. Call your doctor right away if you have the following symptoms of liver problems: </p>   <ul>    <li>feel tired or weak </li>    <li>loss of appetite </li>    <li>upper belly pain </li>    <li>dark amber colored urine </li>    <li>yellowing of your skin or the whites of your eyes </li>   </ul>   <p>The most common side effects of fluvastatin capsules are headache, upset stomach and stomach pain, diarrhea, flu-like symptoms, muscle pain, sinus infection, tiredness, or trouble sleeping. These side effects are usually mild and may go away. The following additional side effects have been reported with fluvastatin capsules: memory loss, and confusion.</p>   <p>Talk to your doctor or pharmacist if you have side effects that bother you or that will not go away. </p>   <p>These are not all the side effects of fluvastatin capsules. Ask your doctor or pharmacist for a complete list. </p>   <p> <span class="Bold">How should I store fluvastatin capsules? </span> </p>   <ul>    <li>Store fluvastatin capsules at room temperature, 20&deg; to 25&deg;C (68&deg; to 77&deg;F). Protect from light. </li>    <li>Do not keep medicine that is out of date or that you no longer need. </li>    <li>Keep fluvastatin capsules out of the reach of children. Be sure that if you throw medicines away, they are out of the reach of children. </li>   </ul>   <p> <span class="Bold">General information about fluvastatin capsules </span> </p>   <p>Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not use fluvastatin capsules for a condition for which they were not prescribed. Do not give fluvastatin capsules to other people, even if they have the same problem you have; they may harm them. </p>   <p>For more information, call 1-888-838-2872, MEDICAL AFFAIRS. </p>   <p> <span class="Bold">What are the ingredients in fluvastatin capsules USP? </span> </p>   <p> <span class="Bold">Active Ingredient: </span>fluvastatin sodium (hydrated form)</p>   <p> <span class="Bold">Inactive Ingredients: </span>black iron oxide, colloidal silicon dioxide, crospovidone, gelatin, lactose monohydrate, magnesium stearate, propylene glycol, red iron oxide, shellac, titanium dioxide, and yellow iron oxide. The imprinting ink may contain potassium hydroxide.</p>   <p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>   <p>Manufactured In Israel By:</p>   <p> <span class="Bold">TEVA PHARMACEUTICAL IND. LTD.</span> </p>   <p>Jerusalem, 91010, Israel</p>   <p>Manufactured For:</p>   <p> <span class="Bold">TEVA PHARMACEUTICALS USA</span> </p>   <p>Sellersville, PA 18960</p>   <p>Rev C. 11/2012</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">PRINCIPAL DISPLAY PANEL</a> <div class="Section toggle-content closed" data-sectioncode="51945-4">   <a name="i4i_Principal_display_panel_id_48aacb9f-3e45-4d2c-a12b-400cccb13d58"></a>  <a name="section-18"></a>   <p></p>    <div class="Figure">    <img src="image.cfm?setid=aad8b373-0aec-4efb-8e61-3d8114b31127&name=acd656cf%2D3edc%2D499c%2D9630%2D17ac45753572%2D06%2Ejpg" alt="Fluvastatin Capsules USP 20 mg 100s Label" />  </div>   <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_df5b4476-3250-4c77-a8dd-3f8f6c35d196"></a>   <a name="section-18.1"></a>    <p></p>    <h2>Fluvastatin Capsules USP 20 mg 100s Label Text</h2>    <p class="First"> <span class="Bold">NDC</span> 0093<span class="Bold">-7442-</span>01</p>    <p> <span class="Bold">FLUVASTATIN<br />Capsules USP<br />20 mg</span> </p>    <p>PHARMACIST: PLEASE DISPENSE WITH<br />ATTACHED PATIENT INFORMATION LEAFLET</p>    <p> <span class="Bold">Rx only</span> </p>    <p> <span class="Bold">100 CAPSULES</span> </p>    <p> <span class="Bold">TEVA</span> </p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">PRINCIPAL DISPLAY PANEL</a> <div class="Section toggle-content closed" data-sectioncode="51945-4">   <a name="i4i_Principal_display_panel_id_23661817-eddc-4a5a-a85c-e3e72558d0e3"></a>  <a name="section-19"></a>   <p></p>    <div class="Figure">    <img src="image.cfm?setid=aad8b373-0aec-4efb-8e61-3d8114b31127&name=acd656cf%2D3edc%2D499c%2D9630%2D17ac45753572%2D07%2Ejpg" alt="Fluvastatin Capsules USP 40 mg 100s Label" />  </div>   <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_4e87e365-e7e4-4827-beec-d0eab936280c"></a>   <a name="section-19.1"></a>    <p></p>    <h2>Fluvastatin Capsules USP 40 mg 100s Label Text</h2>    <p class="First"> <span class="Bold">NDC</span> 0093<span class="Bold">-7443-</span>01</p>    <p> <span class="Bold">FLUVASTATIN<br />Capsules USP<br />40 mg</span> </p>    <p>PHARMACIST: PLEASE DISPENSE WITH<br />ATTACHED PATIENT INFORMATION LEAFLET</p>    <p> <span class="Bold">Rx only</span> </p>    <p> <span class="Bold">100 CAPSULES</span> </p>    <p> <span class="Bold">TEVA</span> </p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">INGREDIENTS AND APPEARANCE</a> <div class="DataElementsTables toggle-content">   <div class="scrollingtable">   <table width="100%" cellpadding="3" cellspacing="0" class="contentTablePetite">     <tbody>      <tr>       <td class="contentTableTitle"><strong>FLUVASTATIN&nbsp; </strong> <br /> <span class="contentTableReg">fluvastatin capsule</span></td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="5" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Information</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Product Type</td>          <td class="formItem">HUMAN PRESCRIPTION DRUG</td>          <td class="formLabel">Item Code (Source)</td>          <td class="formItem">NDC:0093-7442</td>          </tr>          <tr class="formTableRow">           <td class="formLabel" width="30%">Route of Administration</td>          <td class="formItem">ORAL</td>          <td class="formLabel" width="30%">DEA Schedule</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="3">Active Ingredient/Active Moiety</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Basis of Strength</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>FLUVASTATIN SODIUM</strong> (UNII: PYF7O1FV7F) (FLUVASTATIN - UNII:4L066368AS)</td>          <td class="formItem">FLUVASTATIN</td>          <td class="formItem">20&nbsp;mg</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>FERROSOFERRIC OXIDE</strong> (UNII: XM0M87F357)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>SILICON DIOXIDE</strong> (UNII: ETJ7Z6XBU4)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>CROSPOVIDONE</strong> (UNII: 68401960MK)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>GELATIN</strong> (UNII: 2G86QN327L)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>LACTOSE MONOHYDRATE</strong> (UNII: EWQ57Q8I5X)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>MAGNESIUM STEARATE</strong> (UNII: 70097M6I30)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>PROPYLENE GLYCOL</strong> (UNII: 6DC9Q167V3)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>FERRIC OXIDE RED</strong> (UNII: 1K09F3G675)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>SHELLAC</strong> (UNII: 46N107B71O)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>TITANIUM DIOXIDE</strong> (UNII: 15FIX9V2JP)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>FERRIC OXIDE YELLOW</strong> (UNII: EX438O2MRT)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>POTASSIUM HYDROXIDE</strong> (UNII: WZH3C48M4T)</td>          <td class="formItem">&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Characteristics</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Color</td>          <td class="formItem">WHITE (ivory) ,&nbsp;PINK</td>          <td class="formLabel">Score</td>          <td class="formItem">no score</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Shape</td>          <td class="formItem">CAPSULE</td>          <td class="formLabel">Size</td>          <td class="formItem">16mm</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Flavor</td>          <td class="formItem"></td>          <td class="formLabel">Imprint Code</td>          <td class="formItem">TEVA;7442</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Contains</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="5">Packaging</td>          </tr>          <tr>           <th class="formTitle" width="1" scope="col">#</th>          <th class="formTitle" scope="col">Item Code</th>          <th class="formTitle" scope="col">Package Description</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">1</th>          <td class="formItem">NDC:0093-7442-56</td>          <td class="formItem">30 in 1 BOTTLE</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRow">           <th class="formItem" scope="row">2</th>          <td class="formItem">NDC:0093-7442-01</td>          <td class="formItem">100 in 1 BOTTLE</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td><img src="image.cfm?setid=aad8b373-0aec-4efb-8e61-3d8114b31127&name=00093%2D7442%2D56%2Ejpg" style="width:100%;" alt="Image of Product" /></td>      </tr>      <tr>       <td class="normalizer">        <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Marketing Information</span></td>          </tr>          <tr>           <th class="formTitle" scope="col">Marketing Category</th>          <th class="formTitle" scope="col">Application Number or Monograph Citation</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem">ANDA</td>          <td class="formItem">ANDA078407</td>          <td class="formItem">07/05/2012</td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>     </tbody>    </table>  </div>   <div class="scrollingtable">   <table width="100%" cellpadding="3" cellspacing="0" class="contentTablePetite">     <tbody>      <tr>       <td class="contentTableTitle"><strong>FLUVASTATIN&nbsp; </strong> <br /> <span class="contentTableReg">fluvastatin capsule</span></td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="5" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Information</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Product Type</td>          <td class="formItem">HUMAN PRESCRIPTION DRUG</td>          <td class="formLabel">Item Code (Source)</td>          <td class="formItem">NDC:0093-7443</td>          </tr>          <tr class="formTableRow">           <td class="formLabel" width="30%">Route of Administration</td>          <td class="formItem">ORAL</td>          <td class="formLabel" width="30%">DEA Schedule</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="3">Active Ingredient/Active Moiety</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Basis of Strength</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>FLUVASTATIN SODIUM</strong> (UNII: PYF7O1FV7F) (FLUVASTATIN - UNII:4L066368AS)</td>          <td class="formItem">FLUVASTATIN</td>          <td class="formItem">40&nbsp;mg</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>FERROSOFERRIC OXIDE</strong> (UNII: XM0M87F357)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>SILICON DIOXIDE</strong> (UNII: ETJ7Z6XBU4)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>CROSPOVIDONE</strong> (UNII: 68401960MK)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>GELATIN</strong> (UNII: 2G86QN327L)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>LACTOSE MONOHYDRATE</strong> (UNII: EWQ57Q8I5X)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>MAGNESIUM STEARATE</strong> (UNII: 70097M6I30)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>PROPYLENE GLYCOL</strong> (UNII: 6DC9Q167V3)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>FERRIC OXIDE RED</strong> (UNII: 1K09F3G675)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>SHELLAC</strong> (UNII: 46N107B71O)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>TITANIUM DIOXIDE</strong> (UNII: 15FIX9V2JP)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>FERRIC OXIDE YELLOW</strong> (UNII: EX438O2MRT)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>POTASSIUM HYDROXIDE</strong> (UNII: WZH3C48M4T)</td>          <td class="formItem">&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Characteristics</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Color</td>          <td class="formItem">YELLOW,&nbsp;PINK</td>          <td class="formLabel">Score</td>          <td class="formItem">no score</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Shape</td>          <td class="formItem">CAPSULE</td>          <td class="formLabel">Size</td>          <td class="formItem">19mm</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Flavor</td>          <td class="formItem"></td>          <td class="formLabel">Imprint Code</td>          <td class="formItem">TEVA;7443</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Contains</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="5">Packaging</td>          </tr>          <tr>           <th class="formTitle" width="1" scope="col">#</th>          <th class="formTitle" scope="col">Item Code</th>          <th class="formTitle" scope="col">Package Description</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">1</th>          <td class="formItem">NDC:0093-7443-56</td>          <td class="formItem">30 in 1 BOTTLE</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRow">           <th class="formItem" scope="row">2</th>          <td class="formItem">NDC:0093-7443-01</td>          <td class="formItem">100 in 1 BOTTLE</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td><img src="image.cfm?setid=aad8b373-0aec-4efb-8e61-3d8114b31127&name=00093%2D7443%2D56%2Ejpg" style="width:100%;" alt="Image of Product" /></td>      </tr>      <tr>       <td class="normalizer">        <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Marketing Information</span></td>          </tr>          <tr>           <th class="formTitle" scope="col">Marketing Category</th>          <th class="formTitle" scope="col">Application Number or Monograph Citation</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem">ANDA</td>          <td class="formItem">ANDA078407</td>          <td class="formItem">07/05/2012</td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>     </tbody>    </table>  </div>   <div class="scrollingtable">   <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">     <tbody>     <tr>       <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Labeler -&nbsp;</span>Teva Pharmaceuticals USA Inc (118234421) </td>      </tr>     </tbody>   </table>  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li>                                            </ul>                                        <div class="control-nav">                                            <a class="open-all" href="#">View All Sections</a><a class="close-all" href="#">Close All Sections</a>                                        </div>                                        </div>                                    </div>                        </article>                       <div class="articlefooternav">                       <h2>Find additional resources</h2> <strong>(also available in the <a href="#leftmenu">left menu</a>)</strong>                                              <h3>Safety</h3>                       <p>                                                                                                                    <a href="/www.accessdata.fda.gov/scripts/medwatch/ " target="_blank">Report Adverse Events</a>,                                 <a href="http://www.fda.gov/Safety/Recalls/" target="_blank">FDA Safety Recalls</a>,                                 <a href="http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@or+%28@na+%22FLUVASTATIN%22+%29" target="_blank">Presence in Breast Milk</a>                                                   </p>                       <h3>Related Resources</h3>                       <p>                                                                                          <a href="http://vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v:project=medlineplus&query=FLUVASTATIN" target="_blank">Medline Plus</a>,                                                       <a href="/www.clinicaltrials.gov/ct/search?submit=Search&term=FLUVASTATIN" target="_blank">Clinical Trials</a>,                            <a href="#pubmed-menu" id="pubmed-bottom">PubMed</a>,                            <a href="http://www.drugbank.ca/search?utf8=%E2%9C%93&query=APRD00346&search_type=drugs&button=" target="_blank">Biochemical Data Summary</a>                                                  </p>                       <h3>More Info on this Drug</h3>                       <p>                            <a href="#modal-label-archives" class="modal-open">View Label Archives</a>,                             <a href="#modal-rx-norm" class="modal-open">RxNorm</a>,                             <a href="#modal-label-rss" class="modal-open">Get Label RSS Feed</a>                        </p>                    </div>                </div>                                <div class="divider"></div>            </div>        </div>        <!-- Label Archives Modal --><div class="mfp-hide modal" id="modal-label-archives">        <div class="modal-wrapper">        <header><h2>View Label Archives for this drug</h2></header>        <div class="top">        							    	    																																			    																	    	    	                             		       	                                                                                                           <h3 class="long-title">FLUVASTATIN- fluvastatin sodium capsule <br></h3>            <h4>Number of versions: 4</h4>        </div>        <div class="modal-content">                <table class="modal">                    <tbody><tr>                        <th>Published Date</th>                        <th>Version</th>                               <th>Files</th>                    </tr>                                        <tr>                        <td>Nov 4, 2013</td>                        <td>							                                4                             							(current)                         </td>                              <td>                        								                                                            <a class="view-link" href="dailymed/drugInfo.cfm?setid=aad8b373-0aec-4efb-8e61-3d8114b31127" title="View this Label">view</a><span class="sep"> | </span>                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=123279">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Dec 27, 2012</td>                        <td>							                                3                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=96452">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Dec 21, 2012</td>                        <td>							                                2                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=96266">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Jun 13, 2012</td>                        <td>							                                1                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=81197">download</a>                                                    </td>                    </tr>                                    </tbody></table>        </div>        </div></div>        <!-- RxNorm Modal --><div class="mfp-hide modal" id="modal-rx-norm">        <div class="modal-wrapper">        <header><h2>RxNorm</h2></header>        <div class="top">            <h3 class="long-title">FLUVASTATIN- fluvastatin sodium capsule <br></h3>        </div>        <div class="modal-content">        							    	    																																			    																	    	    	                             		       	                                                                                               			                            <table class="modal">                    <tbody><tr>                        <th></th>                        <th>RxCUI</th>                               <th>RxNorm NAME</th>                        <th>RxTTY</th>                    </tr>                                                                                                    <tr class="psn-rxtty">                                                                    <td>1</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=310404">310404</a></td>                              <td>fluvastatin sodium 20 MG Oral Capsule</td>                        <td>PSN</td>                    </tr>                   	                                                    <tr>                                                                    <td>2</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=310404">310404</a></td>                              <td>fluvastatin 20 MG Oral Capsule</td>                        <td>SCD</td>                    </tr>                   	                                                    <tr>                                                                    <td>3</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=310404">310404</a></td>                              <td>fluvastatin (as fluvastatin sodium) 20 MG Oral Capsule</td>                        <td>SY</td>                    </tr>                   	                                                                                <tr class="psn-rxtty">                                                                    <td>4</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=310405">310405</a></td>                              <td>fluvastatin sodium 40 MG Oral Capsule</td>                        <td>PSN</td>                    </tr>                   	                                                    <tr>                                                                    <td>5</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=310405">310405</a></td>                              <td>fluvastatin 40 MG Oral Capsule</td>                        <td>SCD</td>                    </tr>                   	                                                    <tr>                                                                    <td>6</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=310405">310405</a></td>                              <td>fluvastatin (as fluvastatin sodium) 40 MG Oral Capsule</td>                        <td>SY</td>                    </tr>                   	                </tbody></table>                    </div>        </div></div><!-- Label RSS Modal --><div class="mfp-hide modal" id="modal-label-rss">        <header><h2>Get Label RSS Feed for this Drug</h2></header>        <div class="top">            <h3 class="long-title">FLUVASTATIN- fluvastatin sodium capsule <br></h3>        </div>        <div class="modal-content">            <h4>To receive this label RSS feed</h4>            <p>Copy the URL below and paste it into your RSS Reader application.			<p><a href="https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=aad8b373-0aec-4efb-8e61-3d8114b31127" target="_blank">https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=aad8b373-0aec-4efb-8e61-3d8114b31127</a></p>            <h4>To receive all DailyMed Updates for the last seven days</h4>            <p>Copy the URL below and paste it into your RSS Reader application.</p>            <p><a href="https://dailymed.nlm.nih.gov/dailymed/rss.cfm" target="_blank">https://dailymed.nlm.nih.gov/dailymed/rss.cfm</a></p>            <h4>What will I get with the DailyMed RSS feed?</h4>            <p>DailyMed will deliver notification of updates and additions to Drug Label information currently shown on this site through its RSS feed.</p>            <p>DailyMed will deliver this notification to your desktop, Web browser, or e-mail depending on the RSS Reader you select to use. To view updated drug label links, paste the RSS feed address (URL) shown below into a RSS reader, or use a browser which supports RSS feeds, such as Safari for Mac OS X.</p>            <h4>How to discontinue the RSS feed</h4>            <p>If you no longer wish to have this DailyMed RSS service, simply delete the copied URL from your RSS Reader.</p>            <a href="dailymed/rss-updates.cfm" class="rss-icon"></a> <a href="dailymed/rss-updates.cfm">More about getting RSS News & Updates from DailyMed</a>        </div></div>    <!-- this div is only for jQuery --><div class="search-results">    <div class="filter-drop"></div></div><div class="webview"></div><div class="hide-on-mobile"></div>    <div class="mobilenav no-js">        <ul>            <li><a href="dailymed/index.cfm">Home</a></li>            <li>News                <ul>                    <li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>                    <li><a href="dailymed/rss-updates.cfm">Get RSS News &amp; Updates</a></li>                </ul>            </li>            <li>Search                <ul>                    <li><a href="dailymed/advanced-search.cfm">Advanced Search</a></li>                    	                    <li><a href="dailymed/browse-drug-classes.cfm">Browse Drug Classes</a></li>	                    <li><a href="dailymed/archives/index.cfm">Labels Archives</a></li>                                                            <li><a href="http://pillbox.nlm.nih.gov">Tablet/Capsule ID Tool</a></li>                </ul>            </li>                            <li><a href="dailymed/fda-drug-guidance.cfm">FDA Guidances &amp; Information</a></li>                <li>NLM SPL Resources                    <ul>                        <li><a href="dailymed/spl-resources.cfm">Download Data</a>                            <ul>                                <li><a href="dailymed/spl-resources-all-drug-labels.cfm">All Drug Labels</a></li>                                <li><a href="dailymed/spl-resources-all-indexing-files.cfm">All Index Files</a></li>                                <li><a href="dailymed/spl-resources-all-mapping-files.cfm">All Mapping Files</a></li>                            </ul>                        </li>                        <li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>                        <li><a href="dailymed/spl-resources-presentations-articles.cfm">Presentations &amp; Articles</a></li>                    </ul>                </li>                <li>Application Development Support                    <ul>                        <li><a href="dailymed/app-support.cfm">Resources</a>                            <ul>                                <li><a href="dailymed/app-support-web-services.cfm">Web Services</a></li>                                <li><a href="dailymed/app-support-mapping-files.cfm">Mapping Files</a></li>                            </ul>                        </li>                    </ul>                </li>                        <li><a href="dailymed/help.cfm">Help</a></li>                                </ul>    </div>    <footer class="mainFooter">        <div class="container">            <div class="three columns">             <div class="nihnlmlogoprint"><img src="/dailymed/images/nihnlmlogoprint.png" alt="NIH NLM Logo"></div>                <a href="/www.nlm.nih.gov/" class="logo" title="National Library of Medicine | National Institutes of Health"><img src="/dailymed/images/footer-logo.png" width="109" height="37" alt="National Library of Medicine | National Institutes of Health" title="National Library of Medicine | National Institutes of Health" /></a>            </div>                        <div id="share" class="thirteen columns">                <div class="footer-links">                    <ul class="primary">                        <li><a href="dailymed/about-dailymed.cfm" title="About DailyMed">About DailyMed</a><span>|</span></li>                        <li><a href="dailymed/contact-us.cfm" title="Contact Us">Contact Us</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/copyright.html" title="Copyright" target="_blank" rel="bookmark">Copyright</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/privacy.html" title="Privacy" target="_blank" rel="bookmark">Privacy</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/accessibility.html" title="Web Accessibility" target="_blank" rel="bookmark">Web Accessibility</a><span>|</span></li>                        <li><a href="/www.hon.ch/HONcode/Conduct.html?HONConduct393117" target="_blank" title="HONCode Certification">DailyMed is HONCode Certified</a></li>                    </ul>                    <ul class="secondary">                        <li><a href="http://www.nih.gov/" title="National Institutes of Health" target="_blank" rel="bookmark">National Institutes of Health</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/" title="U.S. National Library of Medicine" target="_blank" rel="bookmark">U.S. National Library of Medicine</a><span>|</span></li>                        <li><a href="http://www.hhs.gov/" title="Health &amp; Human Services" target="_blank" rel="bookmark">Health &amp; Human Services</a></li>                    </ul>                    <ul class="secondary mobile">                        <li><a href="http://www.nih.gov/" title="National Institutes of Health" target="_blank" rel="bookmark">NIH</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/" title="U.S. National Library of Medicine" target="_blank" rel="bookmark">NLM</a><span>|</span></li>                        <li><a href="http://www.hhs.gov/" title="Health &amp; Human Services" target="_blank" rel="bookmark">Health &amp; Human Services</a></li>                    </ul>                    <div class="social">                        Share                         <!-- AddThis Button BEGIN -->                        <noscript>: JavaScript needed for Sharing tools</noscript>                        <div class="addthis_toolbox addthis_default_style addthis_16x16_style">							                                                            	                                	            			        	                                                            <a class="email-share" href="mailto:?subject=DailyMed%20Web%20site%20information&amp;Body=I%20would%20like%20to%20share%20this%20page%20from%20the%20DailyMed%20website%20with%20you%3A%0A%0AFLUVASTATIN%2D%20Fluvastatin%20Sodium%20Capsule%0Ahttps%3A%2F%2Fdailymed%2Enlm%2Enih%2Egov%2Fdailymed%2FdrugInfo%2Ecfm%3Fsetid%3Daad8b373%2D0aec%2D4efb%2D8e61%2D3d8114b31127%0A%0ADailyMed%20is%20a%20site%20provided%20by%20The%20National%20Library%20of%20Medicine%20%28NLM%29%20and%20is%20the%20official%20provider%20of%20FDA%20drug%20label%20information%20%28package%20inserts%29%2E" title="Share by Email"></a>                            <a class="addthis_button_facebook"></a>                            <a class="addthis_button_twitter"></a>                            <a class="at300bs at15nc at15t_compact reveal" title="Bookmark &amp; Share" href="/www.addthis.com/bookmark.php?pub=DailyMed&amp;title=DailyMed" target="_blank" style="width: 16px; height: 16px">                                <span style="left: -9999px; position: absolute;">Bookmark &amp; Share</span>                                <img style="width:17px; margin-top: -2px;" src="/dailymed/images/addthis-image.jpg" alt="Bookmark &amp; Share">                            </a>                        </div>                                                <!-- AddThis Button END -->                    </div>                                    </div>            </div>        </div>                <div class="divider"></div>    </footer>    <div class="divider"></div></div><div class="to-top"></div><!-- this div is only for jQuery --><div class="search-results">    <div class="filter-drop"></div></div><div class="webview"></div> <div class="hide-on-mobile"></div><!-- START OF SmartSource Data Collector TAG --><!-- Copyright (c) 1996-2012 Webtrends Inc.  All rights reserved. --><!-- Version: 9.4.0 --><!-- Tag Builder Version: 3.3  --><!-- Created: 1/25/2012 11:57:33 PM --><script type="text/javascript" src="/dailymed/scripts/webtrends.min.js"></script><!-- ----------------------------------------------------------------------------------- --><!-- Warning: The two script blocks below must remain inline. Moving them to an external --><!-- JavaScript include file can cause serious problems with cross-domain tracking.      --><!-- ----------------------------------------------------------------------------------- --><script type="text/javascript">//<![CDATA[var _tag=new WebTrends();_tag.dcsGetId();//]]></script><script type="text/javascript">//<![CDATA[_tag.dcsCustom=function(){// Add custom parameters here.//_tag.DCSext.param_name=param_value;_tag.DCSext.dcsid=_tag.dcsid}_tag.trackAllEvents=true;_tag.dcsCollect();//]]></script><noscript><div><img alt="DCSIMG" id="DCSIMG" width="1" height="1" src="//wtsdc.nlm.nih.gov/dcsm7fmt310000o265ioub7ib_2b7v/njs.gif?dcsuri=/nojavascript&amp;WT.js=No&amp;WT.tv=9.4.0&amp;dcssip=dailymed.nlm.nih.gov&amp;dcsid=dcsm7fmt310000o265ioub7ib_2b7v"/></div></noscript><!-- END OF SmartSource Data Collector TAG --><script type="text/javascript">    setTimeout(function(){var a=document.createElement("script");    var b=document.getElementsByTagName("script")[0];    a.src=document.location.protocol+"//dnn506yrbagrg.cloudfront.net/pages/scripts/0027/2050.js?"+Math.floor(new Date().getTime()/3600000);    a.async=true;a.type="text/javascript";b.parentNode.insertBefore(a,b)}, 1);</script><script type="text/javascript">    function getParameterByName(name) {        name = name.replace(/[\[]/, "\\[").replace(/[\]]/, "\\]");        var regex = new RegExp("[\\?&]" + name + "=([^&#]*)"),            results = regex.exec(location.search);        return results === null ? "" : decodeURIComponent(results[1].replace(/\+/g, " "));    }    /* Tracking label type on search pages */    function CE_READY() {        if(!getParameterByName('labeltype')){           CE2.set(1, "No Label Type");        }        else{            var labeltype = getParameterByName('labeltype');            if(labeltype == 'all'){                CE2.set(1, "All");            }            else if(labeltype == 'human'){                CE2.set(1, "Human");            }            else if(labeltype == 'animal'){                CE2.set(1, "Animal");            }            else{                CE2.set(1, "Unknown");            }        }    }</script>                    <!-- DAP Universal Analytics -->    <script language="javascript" id="_fed_an_ua_tag" src="/dailymed/scripts/Universal-Federated-Analytics-Min.2.0.js?agency=HHS&subagency=NIH&enhlink=true&dclink=true"></script>    <script src="/dailymed/scripts/preview-text.min.js"></script></body></html>    